Introduction {#s1}
============

Cholesterol plays a critical role in cellular homeostasis. As an abundant lipid in the eukaryotic plasma membrane, it modulates vital processes including membrane fluidity and permeability ([@bib24]; [@bib22]) and serves as a precursor for important metabolites including steroid hormones and bile acids ([@bib48]; [@bib7]). The cholesterol biosynthetic pathway in mammalian cells also provides intermediates for essential non-steroid isoprenoids and therefore requires strict regulation ([@bib20]). The endoplasmic-reticulum (ER) resident, polytopic membrane glycoprotein 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) is central to this pathway, catalysing the formation of mevalonate, a crucial isoprenoid precursor. As the rate-limiting enzyme in mevalonate metabolism, HMGCR levels need to be tightly regulated, as dictated by intermediates and products of the mevalonate pathway ([@bib31]). The statin family of drugs, which acts as competitive inhibitors of HMGCR, represents the single most successful approach to reducing plasma cholesterol levels and therefore preventing atherosclerosis-related diseases ([@bib25]). Understanding how HMGCR is regulated is therefore of fundamental biological and clinical importance.

Cholesterol, together with its biosynthetic intermediates and isoprenoid derivatives, regulates HMGCR expression at both the transcriptional and posttranscriptional level ([@bib31]). Low cholesterol induces transcriptional activation of HMGCR through the sterol response element binding proteins (SREBPs) which bind SREs in the promoter region ([@bib47]). In a cholesterol-rich environment, SREBPs are inactive and held in the ER in complex with their cognate chaperone SREBP cleavage-activating protein (SCAP) in association with the ER-resident Insulin-induced genes 1/2 (Insig-1/2) anchor proteins ([@bib17]; [@bib70]). A decrease in membrane cholesterol triggers dissociation of the SCAP-SREBP complex from Insigs and translocation to the Golgi apparatus, where the SREBP transcription factor is proteolytically activated by Site-1 and Site-2 proteases, released into the cytosol and trafficked to the nucleus (reviewed in [@bib26]). Low sterol levels therefore dramatically increase both HMGCR mRNA and extend HMGCR protein half-life, ensuring the resultant elevated enzyme levels stimulate the supply of mevalonate to re-balance cholesterol homeostasis ([@bib20]; [@bib2]). Once cholesterol levels are restored, excess HMGCR is rapidly degraded by the ubiquitin proteasome system (UPS) in a process termed sterol-accelerated degradation ([@bib23]; [@bib50]; [@bib54]). This joint transcriptional and translational regulation of HMGCR is controlled by a host of ER-resident polytopic membrane proteins and represents a finely balanced homeostatic mechanism to rapidly regulate this critical enzyme in response to alterations in intracellular cholesterol. While the ubiquitin-mediated, post-translational regulation of HMGCR is well-established, the identity of the critical mammalian ER-associated degradation (ERAD) E3 ubiquitin ligase(s) responsible for sterol-accelerated HMGCR ERAD remains controversial.

In yeast, *S. cerevisiae* encodes three ERAD E3 ubiquitin ligases, of which Hrd1p (HMG-CoA degradation 1), is named for its ability to degrade yeast HMGCR (Hmg2p) in response to non-sterol isoprenoids ([@bib23]; [@bib1]). The marked expansion and diversification of E3 ligases in mammals makes the situation more complex, as in human cells there are 37 putative E3 ligases involved in ERAD, few of which are well-characterised ([@bib32]). Hrd1 and gp78 represent the two mammalian orthologues of yeast Hrd1p. Hrd1 was not found to regulate HMGCR ([@bib56]; [@bib44]). However, gp78 was reported to be responsible for the sterol-induced degradation of HMGCR as (i) gp78 associates with Insig-1 in a sterol-independent manner, (ii) Insig-1 mediates a sterol-dependent interaction between HMGCR and gp78, (iii) overexpression of the transmembrane domains of gp78 exerted a dominant-negative effect and inhibited HMGCR degradation, and (iv), siRNA-mediated depletion of gp78 resulted in decreased sterol-induced ubiquitination and degradation of HMGCR ([@bib56]). The same laboratory subsequently suggested that the sterol-induced degradation of HMGCR was mediated by two ERAD E3 ubiquitin ligases, with TRC8 involved in addition to gp78 ([@bib29]). However, these findings remain controversial as, despite confirming a role for gp78 in the regulation of Insig-1 ([@bib37]; [@bib61]), an independent study found no evidence for either gp78 or TRC8 in the sterol-induced degradation of HMGCR ([@bib61]). Therefore, the E3 ligase(s) responsible for the sterol-accelerated degradation of HMGCR remain disputed.

The introduction of systematic forward genetic screening approaches to mammalian systems ([@bib5]; [@bib67]) has made the unbiased identification of E3 ubiquitin ligases more tractable, as demonstrated for the viral ([@bib65]; [@bib63]; [@bib58]) and endogenous regulation of MHC-I ([@bib3]; [@bib4]).

To identify the E3 ligases governing HMGCR ERAD, we applied a genome-wide forward genetic screen to a dynamic, cholesterol-sensitive reporter cell line, engineered to express a fluorescent protein fused to endogenous HMGCR. This approach identified cellular genes required for sterol-induced HMGCR degradation, including UBE2G2 and the RNF145 ERAD E3 ubiquitin ligase. The subtle phenotype observed upon RNF145 depletion alone suggested redundant ligase usage. A subsequent, targeted ubiquitome CRISPR/Cas9 screen in RNF145-knockout cells showed RNF145 to be functionally redundant with gp78, the E3 ligase originally implicated in HMGCR degradation. We confirmed that loss of gp78 alone showed no phenotype, while loss of both E3 ligases significantly inhibited the sterol-induced ubiquitination and degradation of HMGCR. Complete stabilisation required additional depletion of a third ligase - Hrd1. We find that endogenous RNF145 is an auto-regulated, sterol-responsive E3 ligase which is recruited to Insig proteins under sterol-replete conditions, thus promoting the regulated ubiquitination and sterol-accelerated degradation of HMGCR. Our data resolve the controversy of the E3 ligases responsible for the post-translational regulation of HMGCR and emphasise the complexity of the mammalian ubiquitin system in fine-tuning sterol-induced HMGCR turnover and cholesterol homeostasis.

Results {#s2}
=======

Targeted knock-in at the endogenous HMGCR locus creates a dynamic, cholesterol-sensitive reporter {#s2-1}
-------------------------------------------------------------------------------------------------

To identify genes involved in the post-translational regulation of HMGCR, we engineered a cell line in which Clover, a bright fluorescent protein ([@bib36]), was fused to the C-terminus of endogenous HMGCR, generating an HMGCR-Clover fusion protein ([Figure 1A](#fig1){ref-type="fig"}). The resulting HMGCR-Clover Hela single-cell clone expresses a dynamic, cholesterol-sensitive fluorescent reporter that is highly responsive to fluctuations in intracellular cholesterol. Basal HMGCR-Clover levels in sterol-replete tissue culture media were undetectable by flow cytometry ([Figure 1B](#fig1){ref-type="fig"}) and phenocopy endogenous WT HMGCR expression ([Figure 1C](#fig1){ref-type="fig"}, compare lanes 1 and 4). Following overnight sterol depletion, a \~ 25 fold increase in HMGCR-Clover expression was detected (shaded grey to blue histogram in [Figure 1D](#fig1){ref-type="fig"}, [Figure 1C](#fig1){ref-type="fig"} (lanes 2 and 5)), representing a combination of increased SREBP-induced transcription and decreased sterol-induced HMGCR degradation. Reintroduction of sterols induced the rapid degradation of HMGCR-Clover (\~80% decrease within 2 hr), confirming the sterol-dependent regulation of the reporter (blue to red histogram in [Figure 1D](#fig1){ref-type="fig"}). Residual, untagged HMGCR detected by immunoblot analysis in the reporter cells under sterol-depleted conditions suggested that at least one HMGCR allele remained untagged ([Figure 1C](#fig1){ref-type="fig"}, compare lanes 2 and 5), which was confirmed by PCR-amplification and sequencing of the genomic locus ([Figure 1---figure supplement 1A--C](#fig1s1){ref-type="fig"}). The unmodified allele allowed us to monitor both tagged and untagged forms of HMGCR. Inhibiting the enzymatic activity of HMGCR with mevastatin also stabilised HMGCR-Clover expression, as did inhibition of the proteasome (bortezomib) or p97/VCP (NMS-873) ([Figure 1E](#fig1){ref-type="fig"}), confirming the rapid, steady-state degradation of the HMGCR reporter. Furthermore, we showed that CRISPR/Cas9-mediated ablation of both Insig-1 and −2 together induced a dramatic increase in HMGCR-Clover expression, equivalent to levels seen following sterol depletion ([Figure 1F](#fig1){ref-type="fig"}). Under these conditions, the SREBP-SCAP complex is not retained in the ER, leading to constitutive SREBP-mediated transcription of HMGCR-Clover, irrespective of the sterol environment. CRISPR-mediated gene disruption of either Insig-1 or −2 alone caused only a small, steady-state rescue of HMGCR-Clover ([Figure 1F](#fig1){ref-type="fig"}), which was more pronounced with the loss of Insig-1 than Insig-2. While Insig-1-deficient cells were unable to completely degrade HMGCR upon sterol addition, only a minor defect in HMGCR degradation was seen in the absence of Insig-2 ([Figure 1F](#fig1){ref-type="fig"}), suggesting that Insig-1 is dominant over Insig-2 under these conditions. Finally, we confirmed that HMGCR-Clover was appropriately localised to the ER by confocal microscopy ([Figure 1G](#fig1){ref-type="fig"}). Thus, HMGCR-Clover is a dynamic, cholesterol-sensitive reporter, which rapidly responds to changes in intracellular cholesterol and is regulated in a proteasome-dependent manner.

![Fluorescent protein tagging of endogenous HMGCR generates a cholesterol-sensitive dynamic reporter.\
(**A**) Schematic showing generation of the HMGCR-Clover reporter. (i) The endogenous HMGCR locus of HeLa cells was modified by transfection of Cas9, sgRNA and a donor template. The 5' and 3' arm of the donor template were designed as homologous sequences encoding the C-terminal region and 3' UTR of the HMGCR gene. The C-terminal Clover tag (green) was appended in frame to the ORF of HMGCR (blue) including a myc-tag (grey) as spacer and an antibiotic resistance cassette flanked by loxP sites. (ii) Cells having stably integrated the recombination construct were enriched by antibiotic selection. (iii) The resistance cassette was removed by transient transfection of Cre recombinase to yield endogenous, C-terminally modified HMGCR (iv). pUb, ubiquitin promoter; ORF, open reading frame; UTR, untranslated region. (**B -- E**) The HMGCR-Clover reporter phenocopies untagged HMGCR. (**B**) HMGCR-Clover expression (grey shaded histogram) as detected by flow cytometry under sterol-replete conditions. (**C**) Immunoblot of HMGCR in sterol-depleted (SD) HeLa WT *vs.* HMGCR-Clover cells -/+sterols (**S**) for 2 hr. For sterol depletion, cells were switched to SD medium (10% LPDS, mevastatin (10 μM), mevalonate (50 μM)) for 16 hr. Whole-cell lysates were separated by SDS-PAGE and HMGCR(-Clover) detected with an HMGCR-specific antibody. (**D**) Cytofluorometric analysis of HMGCR-Clover HeLa cells cultured in sterol-replete (shaded histogram) *vs.* sterol-depleted medium (SD) (16 hr, blue line histogram). Sterols (S) (2 µg/ml 25-hydroxycholesterol, 20 µg/ml cholesterol) were added back for 2 hr (red line histogram). (**E**) Flow cytometric analysis of HMGCR-Clover cells treated overnight with Bortezomib (25 nM), mevastatin (10 μM), or NMS-873 (10 μM) for 8 hr. (**F**) CRISPR/Cas9-mediated depletion of Insig-1 and −2 together (red line histogram) induce a dramatic increase in HMGCR-Clover expression, equivalent to sterol depletion (SD, orange shaded). HMGCR-Clover cells transiently expressing the indicated Insig-1/2 specific sgRNAs (four sgRNAs per gene) were treated as in (**D**) and, where indicated, sterols (**S**) added back for 4 hr (SD + S, bottom row). Representative of ≥3 independent experiments. (**G**) Immunofluorescence analysis of HMGCR-Clover and KDEL (ER marker) expression, showing co-localisation in sterol-depleted (SD, 16 hr) HMGCR-Clover HeLa cells. Scale bar = 20 μm.](elife-40009-fig1){#fig1}

A genome-wide CRISPR/Cas9 screen identifies RNF145 as an E3 ligase required for HMGCR degradation {#s2-2}
-------------------------------------------------------------------------------------------------

To identify genes required for the sterol-induced degradation of HMGCR, we performed a genome-wide CRISPR/Cas9 knockout screen in HMGCR-Clover cells. We took advantage of the rapid decrease in HMGCR-Clover expression following sterol addition to cells starved overnight (16 hr) of sterols ([Figure 1D](#fig1){ref-type="fig"}), and enriched for rare genetic mutants with reduced ability to degrade HMGCR-Clover in response to sterols. To this end, HMGCR-Clover cells were transduced with a genome-wide CRISPR/Cas9 knockout library comprising 10 sgRNAs per gene ([@bib42]). Mutagenised cells were first depleted of sterols overnight; sterols were then reintroduced for 5 hr, at which point rare mutant cells with reduced ability to degrade HMGCR-Clover upon sterol repletion were enriched by fluorescence-activated cell sorting (FACS) ([Figure 2A](#fig2){ref-type="fig"}, gating shown in [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). This process was repeated eight days later to further purify the selected cells. The enriched population contained only a small percentage of cells (1.96% after sort \#1, 24.49% after sort \#2) with increased steady-state HMGCR-Clover expression (green filled histogram in [Figure 2B](#fig2){ref-type="fig"}). However, the majority of sterol-starved cells from this selected population showed impaired degradation of HMGCR-Clover after addition of sterols (compare red *versus* orange filled histogram ([Figure 2B](#fig2){ref-type="fig"}, compare lanes 6 and 9 in [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"})). The broad distribution of this histogram ([Figure 2B](#fig2){ref-type="fig"} red histogram) suggested that the enriched cell population contains a variety of mutants which differ in their ability to degrade HMGCR-Clover.

![Genome-wide CRISPR knockout screen identifies a role for RNF145 in the sterol-dependent degradation of HMGCR.\
(**A - B**) Schematic view of the CRISPR/Cas9 knockout screen workflow and FACS enrichment. (**A**) HMGCR-Clover HeLa cells transduced with a genome-wide sgRNA library targeting 19930 genes (i) were subjected to overnight sterol-starvation followed by sterol repletion for 5 hr (ii, iii, v, vi). Mutants unable to degrade HMGCR-Clover despite sterol repletion (Clover^high^) were enriched by two sequential rounds of FACS (iv, vii) and candidate genes identified by deep sequencing (viii). (**B**) Enrichment of HMGCR-Clover mutants after sort \#1 and sort \#2 (red line histograms, corresponding to steps 'iv' and 'vii' in [Figure 2A](#fig2){ref-type="fig"}) as determined by flow cytometry. Cells were treated as described in [Figure 1D](#fig1){ref-type="fig"}. SD, sterol-depleted; S, sterols. (**C**) Candidate genes identified in the genome-wide knockout screen. Genes scoring above the significance threshold of - logP ≥5 (dotted line) and AUP1 (- logP = 4.7) are highlighted. (**D**) RNF145 depletion mildly impairs sterol-accelerated HMGCR-Clover degradation. HMGCR-Clover cells transiently expressing four independent RNF145-specific sgRNAs (gRNF145\#1--4, red line histogram), individually or as a pool, *vs.* sgB2M (gCTR) were sterol-depleted overnight (middle row, SD) and re-examined by flow cytometry following 2 hr sterol addition (bottom row, SD + S). Representative of ≥3 independent experiments.](elife-40009-fig2){#fig2}

The sgRNAs in the selected cells, and an unselected control library, were sequenced on the Illumina HiSeq platform ([Figure 2A](#fig2){ref-type="fig"} (viii)). Using the RSA algorithm, we identified a set of 11 genes, which showed significant enrichment (-logP \>5) in the selected cells ([Figure 2C](#fig2){ref-type="fig"}). Many of these are known to be required for the sterol-induced degradation of HMGCR ([@bib35]). The screen identified the E2 ubiquitin conjugating enzyme UBE2G2 and its accessory factor AUP1, which recruits UBE2G2 to lipid droplets and membrane E3 ubiquitin ligases ([@bib34]; [@bib30]; [@bib57]; [@bib10]), as well as both Insig-1 and −2 ([@bib70]; [@bib71]; [@bib54]). The role of the remaining hits is summarized ([Table 1](#table1){ref-type="table"}) and validation of selected hits is shown (Insig-1/2, [Figure 1F](#fig1){ref-type="fig"}; UBE2G2, EHD1, GALNT11, LDLR and TECR, [Figure 2 -- figure supplement 1C/D](#fig2s1){ref-type="fig"}).

10.7554/eLife.40009.007

###### Candidate genes (- log(p)≥5) identified in a genome-wide CRISPR/Cas9 screen for proteins involved HMGCR degradation.

  Gene      Full name                                          -log(p)\*   Function
  --------- -------------------------------------------------- ----------- --------------------------------------
  AUP1      Ancient Ubiquitous Protein 1                       4.70        ERAD
  EHD1      EH Domain Containing 1                             6.50        Early endosome membrane fusion
  FAF2      Fas Associated Factor Family Member 2              6.63        ERAD
  FER       Tyrosine-protein Kinase Fer                        6.05        Tyrosine kinase
  GALNT11   Polypeptide N-acetylgalactosaminyltransferase 11   7.03        Protein glycosylation
  INSIG1    Insulin Induced Gene 1                             7.50        Cholesterol metabolism
  INSIG2    Insulin Induced Gene 2                             33.24       Cholesterol metabolism
  LDLR      Low Density Lipoprotein Receptor                   11.44       Cholesterol metabolism
  PPAP2C    Phospholipid Phosphatase 2                         5.67        Glycerolipid synthesis
  RNF145    RING Finger Protein 145                            9.18        E3 ubiquitin ligase
  TECR      Trans-2,3-enoyl CoA Reductase                      7.45        Very-long chain fatty acid synthesis
  UBE2G2    Ubiquitin Conjugating Enzyme E2 G2                 31.14       E2 ubiquitin conjugating enzyme

^\*^Only statistically significant hits (-log(p)≥5) are shown.

Strikingly, the only ER-resident E3 ubiquitin ligase to emerge from the screen is the poorly characterised RNF145. RNF145 shares 27% amino acid identity with TRC8, which is one of the E3 ligases (together with gp78) previously suggested to ubiquitinate HMGCR ([@bib29]). Interestingly, RNF145 also harbours a YLYF motif at its N-terminus, which is similar to the YIYF motif present in the sterol-sensing domain (SSD) of SCAP and HMGCR required for their binding to the Insig proteins ([@bib71]; [@bib54]; [@bib28]; [@bib12]; [@bib73]). The presence of the YLYF motif suggested that RNF145 might itself interact with the Insig proteins and therefore represented a promising candidate from our genetic screen.

To see if we could validate the role of RNF145 in HMGCR degradation, we designed four independent sgRNAs, either targeting RNF145 individually or as a pool. Under cholesterol-replete conditions, no accumulation of the HMGCR-reporter was observed in RNF145-depleted cells (top and middle rows, [Figure 2D](#fig2){ref-type="fig"}), but a small and highly reproducible decrease in HMGCR-Clover degradation was seen following re-introduction of sterols (red histograms, bottom row in [Figure 2D](#fig2){ref-type="fig"}), emphasising the utility of the endogenous fluorescent reporter in identifying subtle phenotypes. Since the identity of the E3 ubiquitin ligases regulating HMGCR turnover remains controversial, the modest effect of RNF145 loss on HMGCR-Clover sterol-induced degradation suggested the involvement of additional ligase(s). Our screen therefore identified both known and novel components implicated in sterol-dependent HMGCR ERAD.

RNF145 together with gp78 are required for HMGCR degradation {#s2-3}
------------------------------------------------------------

If a second E3 ligase is partially redundant with RNF145, its effect should be unmasked in RNF145-deficient cells. We therefore generated a focussed subgenomic sgRNA library targeting 1119 genes of the ubiquitin-proteasome system as described in 'Materials and methods', including 830 predicted E3 ubiquitin ligases, and used this library to screen for genes required for the degradation of HMGCR in RNF145-deficient HMGCR-Clover cells ([Figure 3---figure supplement 4B](#fig3s4){ref-type="fig"}, lane two for knockout validation). Due to the reduced complexity of this focussed library, only a single FACS enrichment step was used ([Figure 3A](#fig3){ref-type="fig"}, red histogram).

![RNF145 together with gp78 are required for HMGCR degradation.\
(**A - B**) FACS enrichment and scatter plot of candidate genes identified in the ubiquitome-targeted knockout screen. (**A**) HMGCR-Clover ΔRNF145\#5 HeLa cells were mutagenized using a targeted ubiquitome-specific sgRNA library and mutant cells showing impaired sterol-dependent degradation of HMGCR-Clover were enriched by FACS. Enrichment is represented by a broad population of Clover^high^ cells in the presence of sterols (S, 2 hr) after overnight sterol depletion (SD, blue to red histogram). (**B**) Genes scoring above the significance threshold of - logP ≥5 (dotted line) are highlighted. (**C - F**) sgRNA targeting of gp78 together with RNF145 increases steady-state HMGCR-Clover and inhibits sterol-accelerated degradation of HMGCR-Clover in sterol-starved cells. (**C**) HMGCR-Clover cells transiently transfected with indicated sgRNAs were sterol-depleted (SD) overnight (blue line histogram) and sterols (2 µg/ml 25-hydroxycholesterol, 20 µg/ml cholesterol) added back (SD + S) for 2 hr (red line histogram or blue shaded histogram for sgB2M (gCTR)). Representative of ≥3 independent experiments. (**D**) Four independent gp78 knockout clones (\#1--4) or WT cells were sterol-depleted (16 hr) ± S (4 hr) and HMGCR levels monitored by immunoblotting. LE, long exposure. (**E**) HMGCR steady-state levels in three RNF145/gp78 double knockout clones (ΔRΔG \#1--3). (**F**) Four RNF145/gp78 double-knockout clones (ΔRΔG \#4--7), RNF145 knockout, and WT cells were sterol-depleted (SD) overnight and HMGCR expression assessed ± sterols (S, 4 hr) by immunoblot analysis.](elife-40009-fig3){#fig3}

Strikingly, this screen identified gp78 (gene name: *AMFR*) ([Figure 3B](#fig3){ref-type="fig"}, [Table 2](#table2){ref-type="table"}), the E3 ubiquitin ligase previously implicated in HMGCR degradation ([@bib29]; [@bib56]; [@bib19]). Taking a combined knockout strategy we asked whether gp78 and RNF145 are together responsible for HMGCR degradation. As predicted by the genetic approach (**[Figure 3C](#fig3){ref-type="fig"} (ii)**), there was no difference in sterol-induced HMGCR-Clover degradation between control and gp78-depleted HMGCR-Clover cells. Gp78 was not, therefore, a false-negative from our initial, genome-wide CRISPR/Cas9 screen ([Figure 2C](#fig2){ref-type="fig"}). Individual knockout of RNF145 again showed that sterol-induced HMGCR-Clover degradation was mildly impaired in RNF145-depleted cells ([Figure 3C](#fig3){ref-type="fig"} (iii)). However, sgRNA-mediated targeting of gp78 together with RNF145 ([Figure 3C](#fig3){ref-type="fig"} (iv), see [Figure 3---figure supplement 4A and B](#fig3s4){ref-type="fig"} lane three for knockout validation), resulted in a significant increase in both steady-state HMGCR-Clover ([Figure 3C](#fig3){ref-type="fig"} (iv) grey to green filled histograms) and an inability to degrade HMGCR-Clover upon addition of sterols to sterol-starved cells ([Figure 3C](#fig3){ref-type="fig"} (iv) blue to red histogram), a phenotype comparable to UBE2G2 deletion ([Figure 3C](#fig3){ref-type="fig"} (v)). Our results therefore suggest a partial functional redundancy between gp78 and RNF145 and imply that both ligases can independently regulate the sterol-induced degradation of HMGCR.

10.7554/eLife.40009.013

###### Candidate genes (-log(p)≥5) identified in a ubiquitome CRISPR/Cas9 screen for proteins mediating HMGCR degradation in RNF145-deficient cells.

  Gene      Full name                                     -log(p)\*   Function
  --------- --------------------------------------------- ----------- -------------------------------------------------
  AMFR      Gp78/Autocrine Motility Factor Receptor       10.87       E3 ubiquitin ligase
  ANKFY1    Ankyrin Repeat And FYVE Domain Containing 1   6.19        Proposed Rab5 effector
  FAF2      Fas Associated Factor Family Member 2         5.05        ERAD
  NPLOC4    NPL4 Homolog                                  7.63        Ubiquitin recognition factor
  RABGEF1   RAB Guanine Nucleotide Exchange Factor 1      8.56        Nucleotide exchange factor, E3 ubiquitin ligase
  UBE2G2    Ubiquitin Conjugating Enzyme E2 G2            13.66       E2 ubiquitin conjugating enzyme

^\*^Only statistically significant hits (-log(p)≥5) are shown.

RNF145 and gp78 regulate endogenous wild type HMGCR {#s2-4}
---------------------------------------------------

To confirm that the phenotypes observed in RNF145- and gp78-deficient HMGCR-Clover cells were representative of endogenous, wild type HMGCR regulation, we deleted RNF145 and/or gp78 from WT HeLa cells and monitored endogenous HMGCR by immunoblot analysis. The sterol-induced degradation of HMGCR was assessed in four RNF145 knockout clones, derived from two different sgRNAs (validation in [Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). No difference in the sterol-induced degradation of HMGCR was seen in these RNF145 knockout clones ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}, compare lanes 6 and 7--10). The subtle effect on HMGCR-Clover expression revealed by flow cytometry ([Figures 2D](#fig2){ref-type="fig"} and [3C](#fig3){ref-type="fig"}) may not be detected by the less sensitive immunoblot analysis. Similarly, loss of gp78 alone ([Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"} for sgRNA validation) did not affect HMGCR degradation ([Figure 3D](#fig3){ref-type="fig"}, compare lanes 6 and 7--10), but loss of gp78 together with RNF145 resulted in a significant rescue of steady state HMGCR ([Figure 3E](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3C](#fig3s3){ref-type="fig"}). Following sterol addition, gp78/RNF145 double-knockout clones showed a marked (although still incomplete) reduction in sterol-induced HMGCR degradation ([Figure 3F](#fig3){ref-type="fig"}, compare lanes 7 + 8 with 9 --12). These data validate the phenotypes exhibited by the HMGCR-Clover reporter cell line and confirm a role for both gp78 and RNF145 in the sterol-induced degradation of endogenous HMGCR.

RNF145 E3 ubiquitin ligase activity is required for HMGCR degradation {#s2-5}
---------------------------------------------------------------------

To determine whether RNF145 E3 ubiquitin ligase activity is required for HMGCR degradation, we complemented a population of gp78/RNF145 double-knockout HMGCR-Clover cells ([Figure 3---figure supplement 4B](#fig3s4){ref-type="fig"}, lane three for knockout validation) with either epitope-tagged wild type RNF145, or a catalytically-inactive RNF145 RING domain mutant (C552A, H554A) ([Figure 4A](#fig4){ref-type="fig"}). The pronounced block in the sterol-induced degradation of HMGCR-Clover was at least partially rescued by expression of wild type, but not the RNF145 RING domain mutant ([Figure 4B](#fig4){ref-type="fig"}, compare blue to red histogram). The E3 ligase activity of RNF145 is therefore critical for HMGCR ERAD.

![RNF145 E3 ligase activity is required for HMGCR degradation.\
(**A**) Exogenous expression of RNF145 and RING-mutant RNF145 in HMGCR-Clover HeLa cells. RNF145/gp78 double-knockout HMGCR-Clover cells were transduced with lentivirus expressing either RNF145-V5 (WT) or a catalytically inactive RING domain mutant RNF145(C552A, H554A)-V5 cDNA (RING mutant) and cell lysates separated by SDS-PAGE and visualised by immunoblot analysis. IB, immunoblot. (**B**) Wild type, but not RING mutant RNF145, complements the RNF145-deficiency phenotype. RNF145/gp78 double-knockout HMGCR-Clover cells (ΔRΔG \#11) were transduced with lentivirus expressing either RNF145-V5 or a catalytically inactive RING domain mutant RNF145(C552A, H554A)-V5 cDNA. Cells were sterol-depleted (16 hr) and after sterol repletion (2 hr), HMGCR-Clover levels were assessed by flow cytometry.](elife-40009-fig4){#fig4}

Endogenous RNF145 is an unstable E3 ligase, whose transcription is sterol-regulated {#s2-6}
-----------------------------------------------------------------------------------

Endogenous RNF145 has a short half-life (\~2 hr) and displayed rapid, proteasome-mediated degradation ([Figure 5A](#fig5){ref-type="fig"} (i)), an observation confirmed in multiple cell lines ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). This rapid turnover of endogenous RNF145 contrasts sharply with the stability of endogenous gp78, which shows little degradation over the 10 hr chase period ([Figure 5A](#fig5){ref-type="fig"} (i)). Although RNF145 and gp78 both target HMGCR for degradation, the two ligases did not appear to be co-regulated as RNF145 stability was unaffected by gp78 and vice-versa ([Figure 5A](#fig5){ref-type="fig"} (i, ii), [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). However, endogenous RNF145 was stabilised by deletion of its cognate E2 enzyme UBE2G2 ([Figure 5B](#fig5){ref-type="fig"}), and, furthermore, the catalytically-inactive RING domain mutant expressed in RNF145-deficient cells (ΔRNF145 \#4 + RNF145-V5 (mut)) exhibited greater abundance at steady-state compared with its wild type counterpart ([Figure 3---figure supplement 4C](#fig3s4){ref-type="fig"}). Together these data show that RNF145 is intrinsically unstable and rapidly turned over in an auto-regulatory manner.

![RNF145 is an intrinsically unstable, sterol-responsive E3 ligase.\
(**A and B**) RNF145 has a short half-life and is auto-regulated by UBE2G2. (**A**) Translational shutoff analysis of gp78 in WT *versus* ΔRNF145 \#4 (**i**) or RNF145 in Δgp78 \#3 cells (ii) treated with cycloheximide (CHX, 1 µg/ml) ± MG132 (20 µg/ml) for the indicated times. Non-specific bands are indicated by an asterisk (\*). Representative of ≥2 independent experiments. (**B**) Immunoblot analysis of WT and ΔUBE2G2 HeLa cells treated with CHX (1 µg/ml) for the indicated times. VCP serves as a loading control. LE, long exposure. An asterisk (\*) signifies non-specific bands. (**C and D**) Sterol depletion induces transcriptional activation and increased levels of RNF145 protein. (**C**) Relative RNF145 and HMGCR mRNA levels as measured by quantitative PCR in HeLa cells grown in 10% FCS (FCS) or sterol-depleted (SD, 10% LPDS + 10 µM mevastatin + 50 µM mevalonate) for 48 hr. Mean ± S.D. (n = 4) and significance are shown, unpaired Students t-test: \*\*\*p≤0.001. (**D**) HeLa cells were grown under sterol-rich or -deplete conditions (±SD, as indicated) for 48 hr in the presence of mevastatin (10 µM) and mevalonate (50 µM) ± complexed cholesterol (Chol:MBCD, 37.5 µM). Whole-cell lysates were separated by SDS-PAGE and underwent immunoblot analysis. Non-specific bands are indicated (\*). Representative of ≥2 independent experiments.\
10.7554/eLife.40009.019Figure 5---source data 1.Raw data from qPCR experiment in [Figure 5C](#fig5){ref-type="fig"}.](elife-40009-fig5){#fig5}

Since RNF145 is rapidly turned over, we aimed to determine whether RNF145 gene transcription was sterol-responsive. Sterol depletion induced RNF145 (\~2.99 ± 0.65 fold increase, p=0.0009) mRNA expression as well as HMGCR (\~12.26 ± 3.16 fold increase, p=0.0004) mRNA expression ([Figure 5C](#fig5){ref-type="fig"}). This accumulation of endogenous RNF145 was suppressed following the addition of methyl beta-cyclodextrin (MBCD)-complexed cholesterol (Chol/MBCD) to the starvation media ([Figure 5D](#fig5){ref-type="fig"}), whereas gp78 abundance remained unaltered ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}). RNF145 is therefore a unique, sterol-regulated E3 ubiquitin ligase whose expression is dependent on the cellular sterol status.

Endogenous RNF145 shows a sterol-sensitive interaction with HMGCR and Insig-1 {#s2-7}
-----------------------------------------------------------------------------

The Insig proteins provide an ER-resident platform for sterol-dependent interactions between HMGCR and its regulatory components ([@bib16]). Since RNF145 is sterol-regulated and degrades HMGCR we initially wanted to know if RNF145 interacts with HMGCR. We found that in sterol-replete but not sterol-deplete conditions, endogenous HMGCR co-immunoprecipitates both epitope-tagged RNF145 ([Figure 6A](#fig6){ref-type="fig"}, [Figure 3---figure supplement 4C](#fig3s4){ref-type="fig"} lane three for relative RNF145-V5 levels upon reconstitution), as well as endogenous RNF145 ([Figure 6B](#fig6){ref-type="fig"}). Initial attempts to ascertain whether this interaction between RNF145 and HMGCR was direct, or mediated *via* the Insig proteins were challenging due to the low expression levels of endogenous RNF145. We circumvented this problem by performing the co-immunoprecipitation in UBE2G2 knockout cells, which express increased levels of endogenous RNF145 ([Figure 5B](#fig5){ref-type="fig"}). Under these conditions, RNF145 showed a clear, sterol-dependent interaction with Insig-1, correlating with RNF145's association with HMGCR ([Figure 6C](#fig6){ref-type="fig"}). Importantly, endogenous RNF145 is not, therefore, continually bound to Insig-1, but, like HMGCR, associates with Insig-1 in a sterol-dependent manner.

![Endogenous RNF145 shows sterol-sensitive binding to Insig-1 and HMGCR.\
(**A**) Exogenous RNF145 shows sterol-sensitive binding to HMGCR. RNF145 knockout cells stably reconstituted with RNF145-V5 (ΔR145 \#4 + R145-V5, as shown in [Figure 3---figure supplement 4C](#fig3s4){ref-type="fig"}, lane 3) were sterol-depleted (SD, 20 hr) and, where indicated, sterols (**S**) added back for 1 hr in the presence of NMS-873 (10 µM, 1.5 hr). RNF145-V5 was affinity-purified (AP) and HMGCR detected by immunoblotting. Representative of ≥3 independent experiments. (**B - C**) Endogenous RNF145 shows sterol-sensitive binding to HMGCR and Insig-1. (**B**) HeLa WT or ΔRNF145 \#4 (∆R) cells were treated as in (**A**), endogenous RNF145 was immunoprecipitated (IP), and RNF145 and HMGCR detected by immunoblot analysis. Non-specific bands are designated by an asterisk (\*). Representative of ≥3 independent experiments. (**C**) HeLa UBE2G2 knockout cells (ΔUBE2G2 \#1) were sterol-depleted (SD, 20 hr) and, where indicated, sterols (**S**) added for 1 hr. Endogenous RNF145 was affinity-purified and following SDS-PAGE separation, Insig-1 and HMGCR detected by immunoblot analysis. Representative of ≥2 independent experiments. (**D - E**) Insigs mediate binding between RNF145 and HMGCR. (**D**) HeLa UBE2G2 knockout cells (ΔUBE2G2 \#1) transfected with a pool of four sgRNAs targeting HMGCR (gHMGCR) or sgRNA targeting B2M (gCTR) were enriched by puromycin selection and sterol-depleted for 20 hr, before adding back sterols for 1 hr + NMS-873 (10 µM, 1.5 hr). Endogenous RNF145 was immunoprecipitated and Insig-1 and HMGCR detected by immunoblot analysis. Non-specific bands are designated by an asterisk (\*). (**E**) HMGCR-Clover HeLa WT or Insig-1+2 knockout (ΔIn-1+2) cells were transfected with a pool of three sgRNAs targeting UBE2G2 (gUBE2G2) and treated as in (**D**). Non-specific bands are designated by an asterisk (\*).](elife-40009-fig6){#fig6}

Binding of RNF145 to Insig-1 was HMGCR-independent ([Figure 6D](#fig6){ref-type="fig"}) and, in the absence of Insigs, RNF145 was unable to bind HMGCR ([Figure 6E](#fig6){ref-type="fig"}, see [Figure 6---figure supplement 1A--C](#fig6s1){ref-type="fig"} for generation of Insig-1+2 knockout cells). Insigs are therefore indispensable for the interaction between RNF145 and HMGCR. These findings emphasize the central role of Insig proteins as scaffolds in the sterol-induced engagement of HMGCR by RNF145.

In the absence of RNF145 and gp78, Hrd1 targets HMGCR for degradation {#s2-8}
---------------------------------------------------------------------

Despite our two genetic screens identifying a requirement for RNF145 and gp78 in HMGCR degradation ([Figures 2C](#fig2){ref-type="fig"} and [3B](#fig3){ref-type="fig"}), the combined loss of these two ligases failed to completely inhibit sterol-induced HMGCR degradation ([Figure 3C](#fig3){ref-type="fig"} (iv); [Figure 7A](#fig7){ref-type="fig"} (ii)). Furthermore, ablation of UBE2G2 in RNF145/gp78 double-knockout cells exacerbated the sterol-dependent degradation defect ([Figure 7A](#fig7){ref-type="fig"} (iv)), predicting the role for an additional E3 ubiquitin ligase(s) utilising UBE2G2 in HMGCR degradation. We therefore assessed whether ablation of either of the two remaining ER-resident E3 ligases known to use UBE2G2, TRC8 ([@bib64]) and Hrd1 ([@bib33]), exacerbated the HMGCR-degradation defect in RNF145/gp78 double-knockout cells ([Figure 7B](#fig7){ref-type="fig"}, [Figure 7---figure supplements 1B](#fig7s1){ref-type="fig"} and [2B](#fig7s2){ref-type="fig"} for knockdown validation). While the loss of TRC8 had no effect on HMGCR-Clover expression, the loss of Hrd1 in RNF145/gp78 double-knockout cells increased steady-state HMGCR-Clover expression and caused a complete block in the sterol-accelerated degradation of HMGCR-Clover ([Figure 7B](#fig7){ref-type="fig"} (ii), [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"} for validation with individual independent sgRNAs). This additive effect of Hrd1 depletion on the sterol-induced turnover of endogenous HMGCR was independently confirmed by immunoblot analysis ([Figure 7C](#fig7){ref-type="fig"}, compare lanes 2, 4 and 6) and was observed as early as 60 min after sterol addition ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}, compare lanes 7 and 9). Importantly, depletion of Hrd1, alone or in combination with depletion of either gp78 or RNF145, did not affect HMGCR-Clover degradation ([Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}). Moreover, TRC8 depletion affected neither steady-state HMGCR-Clover expression, nor sterol-induced HMGCR-Clover degradation ([Figure 7B](#fig7){ref-type="fig"} (iii)). Indeed, despite a functional TRC8 depletion ([Figure 7---figure supplement 2B](#fig7s2){ref-type="fig"} for validation of TRC8 depletion) ([@bib58]), we could detect no role for TRC8, depleted either alone or in combination with RNF145, in the sterol-induced degradation of HMGCR ([Figure 7---figure supplement 2A](#fig7s2){ref-type="fig"}).

![In the absence of RNF145 and gp78, Hrd1 targets HMGCR for ubiquitination and degradation.\
(**A**) Loss of gp78, RNF145 and UBE2G2 exert an additive effect on HMGCR degradation. WT or RNF145/gp78 double knockout (ΔRΔG \#11) HMGCR-Clover HeLa cells transiently expressing sgRNAs targeting UBE2G2 (gUBE2G2) or B2M (gCTR) were enriched by puromycin selection, sterol-depleted (SD) overnight and HMGCR-Clover expression assessed ± sterols (S, 4 hr). Representative of 3 independent experiments. (**B and C**) A targeted gene approach shows that loss of Hrd1 from RNF145/gp78 double knockout cells blocks sterol-accelerated degradation of HMGCR. (**B**) WT and ΔRNF145 Δgp78 (ΔRΔG \#11) HMGCR-Clover cells transfected with sgB2M (gCTR), a pool of 3-4 sgRNAs targeting either Hrd1 (gHrd1), TRC8 (gTRC8) or UBE2G2 (gUBE2G2), were sterol-depleted (SD, 20 hr) and HMGCR-Clover expression assessed by FACS analysis ± sterols (S, 2 hr). (**C**) WT and RNF145/gp78 double knockout cells (ΔRΔG \#7) were transfected with a pool of four Hrd1-specific sgRNAs or gCTR, sterol-depleted overnight before addition of sterols (4 hr) and analysis by SDS-PAGE and immunoblotting. RNF145 and gp78 knockout validation is shown in [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"} (ΔRNF145 \#1) and [Figure 3---figure supplement 3B](#fig3s3){ref-type="fig"} (ΔRΔG \#7), respectively. (**D**) RNF145, gp78 and Hrd1 are required for sterol-accelerated HMGCR ubiquitination. HMGCR was immunoprecipitated (IP) from the indicated cell lines grown in sterol-depleted media (20 hr) ± sterols (1 hr). MG-132 (50 µM) was added 30 min before sterol supplementation. Ubiquitinated HMGCR was detected using an anti-ubiquitin antibody.](elife-40009-fig7){#fig7}

In summary, gp78 with RNF145 are the only combination of ligases whose loss inhibited HMGCR degradation. Hrd1 depletion also delays sterol-induced HMGCR degradation, but only in the absence of RNF145 and gp78.

RNF145, gp78 and Hrd1 are required for sterol-accelerated HMGCR ubiquitination {#s2-9}
------------------------------------------------------------------------------

As a complete block of sterol-accelerated HMGCR degradation required the depletion of all three UBE2G2-dependent E3 ubiquitin ligases, we determined how the sequential depletion of these ligases affected the ubiquitination status of HMGCR. The combined loss of RNF145 with gp78 showed a dramatic reduction in HMGCR ubiquitination, but a complete loss of ubiquitination required the depletion of all three ligases ([Figure 7D](#fig7){ref-type="fig"}). As predicted, depletion of UBE2G2 also caused a marked decrease in HMGCR ubiquitination. Taken together, these results demonstrate the remarkable plasticity of the HMGCR-degradation machinery.

Discussion {#s3}
==========

The generation of a dynamic, cholesterol-sensitive endogenous HMGCR reporter cell line allowed an unbiased genetic approach to identify the cellular machinery required for sterol-accelerated HMGCR degradation. This reporter cell line has the advantage of being able to identify both complete and partial phenotypes and helps explain why the identity of the E3 ubiquitin ligases responsible for the sterol-accelerated degradation of HMGCR has remained controversial. We find that three E3 ubiquitin ligases - RNF145, gp78 and Hrd1 - are together responsible for HMGCR degradation ([Figure 8](#fig8){ref-type="fig"}). The activity of the two primary ligases, RNF145 and gp78 is partially redundant as the loss of gp78 alone did not affect HMGCR degradation, while loss of RNF145 showed only a small reduction on HMGCR degradation. In the absence of both RNF145 and gp78, a third ligase, Hrd1, can compensate and partially regulate HGMCR degradation, but this effect of Hrd1 is only revealed in the absence of both RNF145 and gp78, and in no other identified combination.

![Sterol-induced HMGCR degradation by RNF145, gp78 and Hrd1.\
(i) Under sterol-depleted conditions (shaded orange), HMGCR, Insigs and RNF145 are transcriptionally induced leading to accumulation of RNF145 and HMGCR. Insigs are continually turned over by gp78-mediated polyubiquitination, extracted from the membrane by VCP and degraded by the 26S proteasome. HMGCR stability is dramatically increased as it is not engaged by either RNF145, gp78 or their shared E2 ubiquitin conjugating enzyme UBE2G2 (G2). In the presence of sterols (shaded blue), RNF145 and gp78 are recruited to HMGCR in an Insig-assisted fashion, mediating the sterol-accelerated and UBE2G2-dependent degradation of HMGCR by the ubiquitin-proteasome system. Under these conditions both RNF145 and gp78 can independently ubiquitinate HMGCR, which is then extracted from the ER membrane in a VCP-dependent manner. The stoichiometry and make-up of the different Insig complexes within the ER membrane are unknown. (ii) When both RNF145 and gp78 are not available (ΔRNF145 + Δgp78), Hrd1 and UBE2G2 can promote removal of HMGCR in the presence of sterols.](elife-40009-fig8){#fig8}

Initial reports of a role for gp78 in HMGCR degradation, either alone ([@bib56]) or in combination with TRC8 ([@bib29]), were not reproduced in an independent study ([@bib61]) and so this important issue has remained unresolved. Our initial genome-wide screen successfully identified a single E3 ligase (RNF145) as well as many of the components known to be required for sterol-accelerated HMGCR degradation (e.g. Insig-1/2, UBE2G2, AUP1, FAF2; [Figure 2C](#fig2){ref-type="fig"}) ([@bib55]; [@bib40]; [@bib30]), thus validating the suitability of this genetic approach.

For a small number of validated hits from our screen ([Figure 2C](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}), the effects on sterol-accelerated HMGCR degradation were unanticipated and likely reflect wide-ranging alterations to the protein and lipid environment. Trans-2,3-enoyl CoA reductase (TECR) catalyses the final steps in the synthesis of very long-chain fatty acids (VLCFAs) ([@bib41]) as well as the saturation step in sphingolipid degradation ([@bib66]). Polypeptide N-acetylgalctosaminyltransferase 11 (GALNT11) initiates protein O-linked glycosylation, suggesting that a protein involved in HMGCR regulation requires O-linked glycosylation ([@bib53]). Interestingly, our screen revealed that loss of the LDLR impaired HMGCR-Clover degradation. This finding is unexpected as the cholesterol added to the cells to induce HMGCR degradation was not in the form of LDL. EH domain-containing protein 1 (EHD1) is required for the internalisation and recycling of several plasma membrane receptors, including the LDLR ([@bib45]; [@bib46]) and loss of EDH1 impairs LDLR trafficking with decreased intracellular cholesterol levels ([@bib45]). The other significant hits in the screen (PPAP2C, FER) have not been validated.

The screen also identified the E2 ubiquitin conjugating enzyme UBE2G2 and the E3 ubiquitin ligase RNF145. Depletion of UBE2G2 prevented HMGCR degradation, implying that all ligases involved in HMGCR degradation utilise this E2 enzyme. In contrast, and despite being a high confidence hit in our screen, depletion of RNF145 caused a highly reproducible but small inhibition of sterol-accelerated HMGCR degradation, confirming the sensitivity of the screen to detect partial phenotypes and predicting the requirement for at least one additional UBE2G2-dependent ligase. A subsequent, targeted ubiquitome library screen in an RNF145-knockout reporter cell line confirmed a role for gp78 in HMGCR degradation. Gp78 has previously been shown to use UBE2G2 as its cognate E2 enzyme in the degradation of ERAD substrates ([@bib6]). During preparation of this manuscript, the combined involvement of RNF145 and gp78 in Insig-mediated HMGCR degradation in hamster (CHO) cells was also reported ([@bib28]), confirming the role for these ligases in other species.

The availability of an RNF145-specific polyclonal antibody provides further insight into the expression and activity of endogenous RNF145, without the concerns of overexpression artefacts. RNF145 is an ER-resident E3 ubiquitin ligase with several unique features that make it well-suited for HMGCR regulation. A challenge facing all proteins responsible for cholesterol regulation is that the target they monitor, cholesterol, resides entirely within membranes. Like HMGCR and SCAP, RNF145 contains a putative sterol-sensing domain in its transmembrane region ([@bib12]), suggesting that sterols may facilitate RNF145's association with Insigs. In contrast to Jiang et al., 2018, who reported a constitutive, sterol-independent association between ectopically expressed RNF145 and Insig-1 or −2, we find that endogenous RNF145 interacts with endogenous Insig-1 in a sterol-dependent manner ([Figure 6C](#fig6){ref-type="fig"}), as reported for the interaction of SCAP and HMGCR with the Insig proteins ([@bib38]). The binding of RNF145 to Insig-1 is HMGCR-independent ([Figure 6D](#fig6){ref-type="fig"}). Furthermore, in the absence of Insigs, the RNF145-HMGCR association is lost ([Figure 6E](#fig6){ref-type="fig"}), implying that the interaction between these two proteins is absolutely Insig-dependent. Therefore, sterols trigger the recruitment of RNF145 to HMGCR via Insigs, leading to HMGCR ubiquitination and degradation. This ability of RNF145 to rapidly bind Insigs following sterol availability supports a key role for this ligase in HMGCR regulation.

A striking feature of RNF145 is its short half-life and rapid proteasome-mediated degradation, which contrasts with the long-lived gp78 ([Figure 5A/B](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). RNF145 is an intrinsically unstable ligase whose half-life is regulated through autoubiquitination and was not prolonged on binding to Insig proteins (data not shown). Its stability and turnover is RING- and UBE2G2-dependent, but independent of either the gp78 ([Figure 6A- C](#fig6){ref-type="fig"} ) or Hrd1 E3 ligase ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). As cells become sterol-depleted, the transcriptional increase in RNF145 ([Figure 5C/D](#fig5){ref-type="fig"}) likely anticipates the need to rapidly eliminate HMGCR, once normal cellular sterol levels are restored.

While this sterol-dependent transcriptional increase in RNF145 expression may at first seem counterintuitive, under sterol-deplete conditions the RNF145 ligase is not engaged with Insigs or its HMGCR substrate. The build-up of RNF145 predicts the restoration of sterol concentrations allowing RNF145 to immediately engage with, and degrade its HMGCR substrate. Thus the build-up of RNF145 anticipates its critical role in the restoration of cellular cholesterol homeostasis.

RNF145 transcription was reported to be regulated by the sterol-responsive Liver X Receptor (LXR) family of transcription factors ([@bib12]; [@bib73]), which transcriptionally activate cholesterol efflux pumps (ABCA1, ABCG1) ([@bib13]; [@bib18]) and the IDOL E3 ubiquitin ligase, which targets the LDLR for degradation ([@bib72]). Pharmacological treatment of HeLa cells with the LXR inducer (GW3965) increased protein levels of ABCA1, but RNF145 transcript levels were not significantly increased ([Figure 5 -- figure supplement 2A/B](#fig5s2){ref-type="fig"}). In HeLa cells, therefore, the increased expression of RNF145 following cholesterol starvation is not primarily driven by the LXR pathway.

While it is not unusual for more than one ligase to be required for substrate ERAD degradation ([@bib11]; [@bib43]; [@bib59]), the redundancy in HMGCR turnover is intriguing. This may simply reflect the central role of HMGCR in the mevalonate pathway and the importance of a fail-safe mechanism of HMGCR regulation to both maintain substrates for non-sterol isoprenoid synthesis and prevent cholesterol overproduction. Alternative explanations can also be considered, particularly as the properties of RNF145 and gp78 are so different. Under sterol-deplete conditions gp78 also regulates the degradation of Insig-1, but following addition of sterols, the association of Insigs with SCAP displaces Insigs binding to gp78 ([@bib71]; [@bib37]). Different Insig-associated complexes are therefore likely to co-exist within the ER membrane, under both sterol-replete and -deplete conditions, and will reflect the sterol microenvironment of the ER ([@bib21]). Under these circumstances it might be advantageous to have more than one ligase regulating HMGCR. Alternatively, gp78 may provide basal control of the reductase, which can then be 'fine-tuned' by the sterol-responsive RNF145, reflecting the sterol concentration of the local ER environment. Further understanding of the stoichiometry and nature of the different Insig complexes within the ER membrane will be important. While all cells need to regulate their intracellular cholesterol, the contribution of each ligase to sterol regulation may also depend on their differential tissue expression. In this regard, liver-specific ablation of gp78 in mice has been reported to lead to increased steady-state levels of hepatocyte HMGCR ([@bib39]), whereas gp78 knockout MEFs show no apparent impairment in HMGCR degradation ([@bib61]). Further delineation of the contribution of each ligase to HMGCR degradation in different tissues and cell types will be important.

A role for the Hrd1 E3 ligase in HMGCR regulation was unanticipated, and both orthologues (gp78 and Hrd1) of yeast Hrd1p, which regulates yeast HMGCR (Hmg2p), are therefore involved in mammalian HMGCR turnover. The best recognised function of Hrd1 is the ubiquitination of misfolded or unassembled ER-lumenal and membrane proteins targeted for ERAD ([@bib52]; [@bib62]; [@bib9]). Our finding that Hrd1 is only involved in HMGCR regulation when the other two ligases are absent, suggests that under sterol-rich conditions, and in the absence of RNF145 or gp78, conformational changes in the sterol-sensing domains of HMGCR may lead to a less ordered state and be recognised and targeted by the Hrd1 quality control pathway. Ligand-induced selective and reversible local misfolding in Hmg2p, dubbed 'mallostery', is a suggested mode of recognition by Hrd1p ([@bib68]; [@bib69]).

The mechanism underlying recognition of HMGCR by Hrd1 is unclear, and whether the Hrd1 complex directly recognises sterol-induced structural changes as seen with Hmg2 degradation in yeast is unknown. Hrd1 might utilise the Insig proteins as scaffolds for HMGCR binding. This is partially borne out in the complete rescue of HMGCR in Insig-1 and −2 depleted cells ([Figure 1F](#fig1){ref-type="fig"}). These mechanisms are not mutually exclusive and suggest that the contributions by different ligases may represent a regulated misfolding event as part of a ligand-mediated control of HMGCR stability. Further investigation is needed to clearly determine their contribution to HMGCR regulation.

In summary, our unbiased approach to identify proteins involved in sterol-regulated HMGCR degradation resolves the ambiguity of the responsible E3 ubiquitin ligases, and uncovers additional control points in modulating the activity of this important enzyme in health and disease.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type                   Designation                                Source                       Identifiers                                                      Additional\
                                                                                                                                                                          information
  ------------------------------ ------------------------------------------ ---------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------------
  Antibody                       anti-gp78 (rabbit polyclonal)              ProteinTech, 16675--1-AP     RRID:[AB_2226463](https://scicrunch.org/resolver/AB_2226463)     WB (1:1000)

  Antibody                       anti-ubiquitin\                            Life Sensors,\               RRID:[AB_2716558](https://scicrunch.org/resolver/AB_2716558)     WB (1:1000)
                                 (mouse monoclonal)                         VU101                                                                                         

  Antibody                       anti-V5 tag (mouse monoclonal)             Abcam, ab27671               RRID:[AB_471093](https://scicrunch.org/resolver/AB_471093)       WB (1:1000)

  Antibody                       anti-Insig-1 (rabbit polyclonal)           Abcam, ab70784               RRID:[AB_1269181](https://scicrunch.org/resolver/AB_1269181)     WB (1:1000)

  Antibody                       anti-Hrd1 (rabbit polyclonal)              Abgent,\                     RRID:[AB_2199838](https://scicrunch.org/resolver/AB_2199838)     WB (1:5000)
                                                                            AP2184a                                                                                       

  Antibody                       anti-TRC8 (rabbit polyclonal)              Santa Cruz,\                 RRID:[AB_2238721](https://scicrunch.org/resolver/AB_2238721)     WB (1:2000)
                                                                            sc-68373                                                                                      

  Antibody                       anti-HMGCR (mouse monoclonal)              Santa Cruz, sc-271595        RRID:[AB_10650274](https://scicrunch.org/resolver/AB_10650274)   WB (1:1000)

  Antibody                       anti-UBE2G2 (mouse monoclonal)             Santa Cruz Biotechnology,\   RRID:[AB_1130984](https://scicrunch.org/resolver/AB_1130984)     WB (1:1000)
                                                                            sc-100613                                                                                     

  Recombinant DNA reagent        pSpCas9(BB)−2A-\                           Addgene \#48139              n/a                                                              
                                 Puro V1 (plasmid)                                                                                                                        

  Recombinant DNA reagent        pSpCas9(BB)−2A-Puro V2 (plasmid)           Addgene \#62988              n/a                                                              

  Recombinant DNA reagent        pKLV-U6gRNA(BbsI)-PGKpuro2ABFP (plasmid)   Addgene \# 50946             n/a                                                              

  Recombinant DNA reagent        genome-wide sgRNA library                  other                        n/a                                                              kind gift from the Bassik lab (Stanford University), PMID: 28474669

  Recombinant DNA reagent        ubiquitome sgRNA library                   this study                   n/a                                                              Generated by Lehner and Nathan labs

  Peptide, recombinant protein   V5 peptide                                 Sigma-Aldrich                V7754-4MG                                                        

  Chemical\                      lipoprotein-deficient serum (LPDS)         Biosera                      FB-1001L/100                                                     
  compound, drug                                                                                                                                                          

  Chemical\                      digitonin                                  Merck                        300410--5 GM                                                     
  compound, drug                                                                                                                                                          

  Chemical\                      mevastatin                                 Sigma-Aldrich                M2537-5MG                                                        
  compound, drug                                                                                                                                                          

  Chemical\                      mevalonolactone                            Sigma-Aldrich                M4467-1G                                                         
  compound, drug                                                                                                                                                          

  Chemical\                      cholesterol                                Sigma-Aldrich                C3045-5G                                                         
  compound, drug                                                                                                                                                          

  Chemical\                      25-hydroxycholesterol                      Sigma-Aldrich                H1015-10MG                                                       
  compound, drug                                                                                                                                                          

  Chemical\                      methyl-β-cyclodextrin (MBCD)               Sigma-Aldrich                332615--1G                                                       
  compound, drug                                                                                                                                                          

  Chemical\                      NMS-873                                    Selleckchem                  s728501                                                          
  compound, drug                                                                                                                                                          

  Chemical\                      cycloheximide                              Sigma-Aldrich                C-7698                                                           
  compound, drug                                                                                                                                                          

  Chemical\                      IgG Sepharose\                             GE Healthcare                17-0969-01                                                       
  compound, drug                 6 Fast Flow                                                                                                                              

  Chemical\                      Protein A-Sepharose                        Sigma-Aldrich                P3391-1.5G                                                       
  compound, drug                                                                                                                                                          

  Chemical\                      iodoacetamide                              Sigma-Aldrich                I1149-5G                                                         
  compound, drug                                                                                                                                                          

  Chemical\                      cOmplete protease inhibitor                Roche                        27368400                                                         
  compound, drug                                                                                                                                                          

  Chemical compound, drug        phenylmethyl\                              Roche                        20039220                                                         
                                 sulfonyl fluoride (PMSF)                                                                                                                 

  Chemical compound, drug        N-ethylmaleimide (NEM)                     Sigma-Aldrich                E3876-5G                                                         

  Chemical compound, drug        puromycin                                  Cayman Chemicals             13884                                                            

  Chemical compound, drug        hygromycin B                               Invitrogen                   10687010                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Plasmids and expression constructs {#s4-1}
----------------------------------

Single guide RNAs (sgRNAs) were cloned into pSpCas9(BB)−2A-Puro V1 (Addgene \#48139, deposited by Dr. Feng Zhang), pSpCas9(BB)−2A-Puro V2 (Addgene \#62988, deposited by Dr. Feng Zhang) as previously described ([@bib49]). The genome-wide sgRNA library ([@bib42]) was a kind gift from the Bassik lab (Stanford University). To generate the ubiquitome sgRNA library, sgRNAs (sgRNA sequences in [Supplementary file 1](#supp1){ref-type="supplementary-material"}) were cloned into pKLV-U6gRNA(BbsI)-PGKpuro2ABFP (Addgene \# 50946) as reported previously ([@bib15]). To generate RNF145 expression plasmids, the RNF145 CDS, PCR amplified from an RNF145 IMAGE clone (Source Bioscience, Nottingham, UK), was cloned into pHRSIN-P~SFFV~-GFP-P~PGK~-Hygromycin^R^ (BamHI, NotI) ([@bib14]), replacing GFP with the transgene. To create RNF145-V5, the RNF145 CDS was Gibson-cloned into pHRSIN-P~SFFV~-P~PGK~-Hygromycin^R^ containing a downstream in-frame V5-tag. RNF145-V5 RING domain mutations (C552A, H554A) were introduced by PCR amplification of RNF145-V5 fragments with primers encoding C552A and H554A mutations and RNF145(C552A, H554A)-V5 was introduced into pHRSIN-P~SFFV~-P~PGK~-Hygromycin^R^ by Gibson assembly. FLAG-NLS-Cas9 was cloned from the lentiCRISPR v2 ([@bib51]) (Addgene \#49535, deposited by Feng Zhang) into pHRSIN.pSFFV MCS(+) pSV40 Blast (BamHI, NotI).

Compounds {#s4-2}
---------

The following compounds were used in this study: Dulbecco's Modified Eagle's Medium high glucose (DMEM; Sigma-Aldrich, 6429--500 ml), foetal calf serum (FCS; Seralab (catalogue no: EU-000, SLI batch: E8060012, Supplier batch: A5020012) and Life Technologies (catalogue no: 10270, lot: 42G4179K)), lipoprotein-deficient serum (LPDS; biosera, FB-1001L/100), mevastatin (Sigma-Aldrich, M2537-5MG), mevalonolactone (Sigma-Aldrich, M4467-1G), cholesterol (Sigma-Aldrich, C3045-5G), 25-hydroxycholesterol (Sigma-Aldrich, H1015-10MG), methyl-β-cyclodextrin (MBCD; Sigma-Aldrich, 332615--1G), GW3965 HCl (Sigma-Aldrich, G6295), bortezomib/PS-341 (BostonBiochem, I-200), (S)-MG132 (Cayman Chemicals, 10012628), NMS-873 (Selleckchem, s728501), digitonin (Merck, 300410--5 GM) (1% digitonin for immunoprecipitation experiments was generated by using the soluble supernatant of a 2% digitonin solution which had been left rotating with a small amount of CL4B beads overnight), cycloheximide (Sigma-Aldrich, C-7698), IgG Sepharose^TM^ 6 Fast Flow (GE Healthcare, 17-0969-01), ProLong Gold Antifade Mountant with DAPI (Thermo Fisher), bovine serum albumin (BSA; Sigma-Aldrich, A4503-10G), Protein A-Sepharose^R^ (Sigma-Aldrich, P3391-1.5G), iodoacetamide (IAA; Sigma-Aldrich, I1149-5G), cOmplete protease inhibitor (EDTA-free; Roche, 27368400), phenylmethylsulfonyl fluoride (PMSF; Roche, 20039220), V5 peptide (Sigma-Aldrich, V7754-4MG), N-ethylmaleimide (NEM; Sigma-Aldrich, E3876-5G), puromycin (Cayman Chemicals, 13884), hygromycin B (Invitrogen, 10687010), Penicillin-Streptomycin (10,000 U/mL; Thermo Fisher, 15140122).

Antibodies {#s4-3}
----------

Antibodies specific for the following targets were used for immunoblotting analysis: Insig-1 (rabbit; Abcam, ab70784), Hrd1 (rabbit; Abgent, AP2184a), TRC8 (rabbit; Santa Cruz, sc-68373), tubulin (mouse; Sigma, T9026), VCP (mouse; abcam, ab11433), β-actin (mouse; Sigma-Aldrich, A5316), calnexin (mouse; AF8, kind gift from M Brenner, Harvard Medical School), calreticulin (rabbit; Pierce, PA3-900), HMGCR (mouse; Santa Cruz, sc-271595), HMGCR (rabbit; Abcam, ab174830), gp78 (rabbit; ProteinTech, 16675--1-AP), Insig-1 (rabbit; Abcam, ab70784), RNF145 (rabbit; ProteinTech, 24524-I-AP), V5 (mouse; Abcam, ab27671), VU-1 ubiquitin (mouse; Life Sensors, VU101), UBE2G2 (mouse; Santa Cruz, sc-100613), GFP (rabbit; Thermo Fisher Scientific, A11122), KDEL (mouse; Enzo, 10C3), HRP-conjugated anti-mouse and anti-rabbit (goat; Jackson ImmunoResearch), TrueBlot Anti-Rabbit-HRP (Rockland, 18-8816-31), TrueBlot Anti-Mouse-HRP ULTRA (Rockland, 18-8817-30). Alexa Fluor 488 (goat anti-rabbit; Thermo Fisher), Alexa Fluor 568 (goat anti-mouse; Thermo Fisher) were used as secondary antibodies for immunofluorescence microscopy. Anti-MHC-I (W6/32; mouse) and Alexa Fluor 647 (rabbit anti-mouse; Thermo Fisher) were used for cytofluorometric analysis.

Cell culture {#s4-4}
------------

HeLa, HEK-293T, and HepG2 cells were maintained in DMEM +10% FCS+penicillin/streptomycin (5% CO~2~, 37°C). HeLa cells were obtained from ECACC. HEK-293T and HepG2 cells were obtained from ATCC. HeLa and HepG2 cells were authenticated by STR profiling (Eurofins Genomics). All cell lines tested mycoplasma negative (Lonza MycoAlert). Transfection of HeLa cells was performed using the TransIT-HeLa MONSTER kit (Mirus) according to the manufacturer's instructions. In sort, cells were seeded at low confluency in 12-well tissue culture plates and the next day transfection mix (1 µg DNA, 3 µl TransIT-HeLa reagent +2 µl MONSTER reagent in OptiMEM (Gibco)) was added. Alternatively, reverse transfection was performed by seeding 3.5\*10^5^ cells per well of a 12-well plate to the transfection mix on the day of transfection. For co-transfection of multiple sgRNA plasmids, equal amounts of each plasmid were added up to 1 µg.

CRISPR/Cas9-mediated gene knockout {#s4-5}
----------------------------------

CRISPR/Cas9-mediated genomic editing was performed according to Ran *et al.* ([@bib49]). For generation of knockout cell lines, cells were transfected with pSpCas9(BB)−2A-Puro (PX459) V1.0 or V2.0 (Addgene \#48139, and \#62988 respectively; deposited by Dr. Feng Zhang) containing a sgRNA specific for the targeted gene of interest. Guide RNA sequences are listed in [Supplementary file 2](#supp2){ref-type="supplementary-material"}. Cells were cultured for an additional 24 hr before selection with puromycin (2 µg/ml) at low confluency for 72 hr. The resulting mixed knockout populations were used to generate single-cell clones by limiting dilution or fluorescence-assisted single-cell sorting. A detailed list of single cell knockout clones used in this study can be found in [Supplementary file 3](#supp3){ref-type="supplementary-material"}. Gene disruption was validated by immunoblotting, immunoprecipitation and/or targeted genomic sequencing.

CRISPR/Cas9-mediated gene knock-in {#s4-6}
----------------------------------

An HMGCR-Clover knock-in donor template was created by Gibson assembly of \~1 kb flanking homology arms, PCR-amplified from HeLa genomic DNA, and the NsiI and PciI digested backbone from pMAX-GFP (Amaxa) cloned into the loxP-Ub-Puro cassette from pDonor loxP Ub-Puro (a kind gift from Ron Kopito, Stanford University). Each arm was amplified using nested PCR. The 5\' arm was amplified using 5'-GATGCAGCACAGAATGTTGGTAG-3' and 5'-CAATGCCCATGTTCCAGTTCAG-3', followed by 5'-CAATGCCCATGTTCCAGTTCAG-3' and 5'-CAGCTGCACCATGCCATCTATAG-3'. The 3\' arm was amplified using the following primer pairs: 5'-CCAAGGAGCTTGCACCAAGAAG-3' and 5'-CTAAGGTCCCAGTCTTGCTTG-3'. The product served as template for a subsequent PCR step using the primers 5'-CCAAGGAGCTTGCACCAAGAAG-3' and 5'-GTCACCCTCATCTAAGCAAC-3'. Overhangs required for Gibson assembly were introduced by PCR. HeLa cells were co-transfected with Cas9, sgRNA targeting immediately downstream of the HMGCR stop codon and donor template. Three different donor templates were simultaneously transfected, each differing in the drug resistance marker (puromycin, hygromycin and blasticidin). The transfected cells were treated with the three antibiotics five days *post* transfection until only drug-resistant cells remained. The resulting population was transfected with Cre-recombinase in pHRSIN MCS(+) IRES mCherry pGK Hygro. mCherry positive cells were single-cell cloned by FACS.

Genetic validation of HMGCR-Clover knock-in cells {#s4-7}
-------------------------------------------------

To confirm the knock-in of a myc- and Clover-tag downstream of the HMGCR coding sequence, genomic DNA was isolated from HeLa HMGCR-Clover cells using the Quick-gDNA MicroPrep kit (Zymo Research). The genomic sequence encoding the myc- and Clover-tags and flanking 5' and 3' homology regions were amplified using the following primer combination: 5'- ACTATTCATCTACTGTAGTTCCAAGTTAAAATTCTACACTC-3', 5'- GCATGTAAAGCACTAAACTGTGTTCAGATCTGAGGAGTC-3'. PCR products were separated by agarose gel electrophoresis, gel excised and analysed by Sanger sequencing.

Lentivirus production and transductions {#s4-8}
---------------------------------------

HEK-293T cells were transfected with a lentiviral expression vector, the packaging vectors pCMVΔR8.91 and pMD.G at a ratio of 1:0.7:0.3 using TransIT-293 (Mirus) as recommended by the manufacturer. For production of CRISPR library virus, HEK-293T cells were transfected as above in 15 cm tissue culture plates. 48 hr *post* transfection, virus-containing media was collected, filtered (0.45 µm pore size) and directly added to target cells or frozen (−80°C) for long-term storage. Typically, cells were transduced in 6-well tissue culture plates at an M.O.I. \<1 and selected with puromycin (2 µg/ml) or hygromycin B (200 µg/ml). To generate HeLa HMGCR-Clover stably expressing Cas9, HeLa HMGCR-Clover cells were transduced with pHRSIN-P~SFFV~-Cas9-P~PGK~-Hygromycin^R^ and stable integrants selected with hygromycin B. Cas9 activity was confirmed by transduction with pKLV encoding a β−2-microglobulin (B2M)-targeting sgRNA followed by puromycin selection. MHC-I surface expression was assessed by flow cytometry in puromycin-resistant cells five days post transduction. Typically,\~90% reduction of cell surface MHC-I expression was observed.

Fluorescent PCR {#s4-9}
---------------

To identify CRISPR-induced frame-shift mutations, genomic DNA was extracted from wild type HeLa cells and RNF145 CRISPR clones using the Quick-gDNA MicroPrep kit (Zymo Research) followed by nested PCR of the genomic region 5' and 3' of the predicted sgRNA binding site. One in each primer pair for the second PCR was 5' modified with 6-FAM^TM^ (fluorescein, Sigma-Aldrich). Primer sequences were as follows: For sgRNA \#8 PCR1_Forward: CAGAATGCTCACTAGAAGATTAG, PCR1_Reverse: GTAGTATACGTTCTCACATAG, PCR2_Forward: GTGATGTAGACACTCACCTAC and PCR2_Reverse: GTGACAACCTATTAGATTCGTG. PCR products were detected using an ABI 3730xl DNA Analyser.

Flow cytometry and Fluorescence-activated cell sorting (FACS) {#s4-10}
-------------------------------------------------------------

Cells were collected by trypsinisation and analysed using a FACS Calibur (BD) or an LSR Fortessa (BD). Flow cytometry data was analysed using the FlowJo software package. Cells resuspended in sorting buffer (PBS + 10 mM HEPES +2% FCS) were filtered through a 50 µm filter, and sorted on an Influx machine (BD), or, for the ubiquitome CRISPR/Cas9 screen, on a FACS Melody (BD). Sorted cells were collected in DMEM +50% FCS and subsequently cultured in DMEM +10% FCS+penicillin/streptomycin. For MHC-I flow cytometric analysis, cells resuspended in cold PBS were incubated with W6/32 (20 min, 4°C), washed twice and then incubated with Alexa-647-labelled anti-mouse antibody (15 min, 4°C). Cells were washed twice and resuspended in PBS.

CRISPR/Cas9 knockout screens {#s4-11}
----------------------------

For genome-wide and ubiquitome-library CRISPR/Cas9 knockout screens, 10^8^ and 1.2\*10^7^ HeLa HMGCR-Clover (Cas9) or ΔRNF145 \#6 (Cas9), respectively, were transduced at M.O.I. \~ 0.3 by spinfection (750xg, 60 min, 37°C). Transduction efficiency was determined *via* flow-cytometry-based measurement of mCherry (genome-wide screen) or BFP (ubiquitome screen) expression 48--72 hr *post* infection. Transduced cells were enriched by puromycin selection (2 µg/ml (genome-wide screen), 1 µg/ml (ubiquitome-library screen)). On day 8 (genome-wide screen) or day 7 (ubiquitome-library screen) post transduction, cells were rinsed extensively with PBS and cultured overnight in starvation medium (DMEM +10% LPDS+10 µM mevastatin +penicillin/streptomycin) before sterol addition (2 µg/ml 25-hydroxycholesterol and 20 µg/ml cholesterol for 5 hr). An initial FACS selection ('sort \#1') on cells expressing high levels (\~0.3--0.6% of overall population) of HMGCR-Clover (HMGCR-Clover^high^) was performed. 2\*10^5^ (genome-wide screen) and \~10^5^ (ubiquitome-library screen) sorted cells were pelleted and DNA was extracted using the Quick-gDNA MicroPrep kit (Zymo Research). To gauge sgRNA enrichment, DNA was extracted from 3\*10^6^ (genome-wide library screen) or 6\*10^6^ (ubiquitome library screen) cells pre-sort using the Gentra Puregene Core kit A (Qiagen). Cells in the genome-wide screen were subjected to a second round of sterol deprivation and sort (see above) after expansion of initially 2.5\*10^5^ sorted cells for 8 days. Sorted cells were cultured until 5\*10^6^ cells could be harvested for genomic DNA extraction using the Gentra Puregene Core kit A (Qiagen). Individual integrated sgRNA sequences were amplified by two sequential rounds of PCR, the latter introducing adaptors for Illumina sequencing ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). Sequencing was carried out using the Illumina HighSeq (genome-wide screen) and MiniSeq (ubiquitome-library screen) platforms. Illumina HiSeq data was analysed as described previously ([@bib60]). Guide RNA counts were analysed with the RSA algorithm under default settings ([@bib35]). Of note, a gene's calculated high significance value and therefore high enrichment in the selected population does not necessarily reflect its importance relative to genes with lower significance values/enrichment, since gene disruption can be incomplete or lethal phenotypes might evade enrichment.

Quantitative PCR {#s4-12}
----------------

Whole-cell RNA was isolated with the RNeasy Plus Mini Kit (Qiagen, Venlo, Netherlands) and reverse transcribed using Oligo(dT)15 primer (Promega, C110A) and SuperScript^TM^ III reverse transcriptase (Invitrogen). Transcript levels were determined in triplicate using SYBR Green PCR Master Mix (Applied Biosystems) in a real time PCR thermocycler (7500 Real Time PCR System, Applied Biosystems). Primers used for target amplification can be found in [Supplementary file 5](#supp5){ref-type="supplementary-material"}. RNA quantification was performed using the ΔΔCT method. GAPDH transcript levels were used for normalization. Raw data can be found in [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"} and [Figure 5---figure supplement 2---source data 1](#fig5s2sdata1){ref-type="supplementary-material"}.

Sterol depletion assays {#s4-13}
-----------------------

Typically, HeLa cells at \~50% confluency were washed five times with PBS and cultured for 16--20 hr in starvation medium (DMEM +10% LPDS+10 µM mevastatin +50 µM mevalonate +penicillin/streptomycin) before addition of 25-hydroxycholesterol (2 µg/ml) and cholesterol (20 µg/ml) to analyse sterol-accelerated protein degradation.

Chol:MBCD complex preparation {#s4-14}
-----------------------------

Complexation of cholesterol (2.5 mM) with MBCD (25 mM) was performed according to Christian *et al.* ([@bib8]). An emulsion of cholesterol powder (final: 2.5 mM) and an MBCD solution (25 mM) was produced by vortexing and tip sonication (1 min in 10 s intervals), and continuously mixed for 16 hr at 37°C. The solution was sterile filtered (0.45 μm PVDF pore size) and stored at −20°C.

Preparation of sterols and mevalonate {#s4-15}
-------------------------------------

Sterols were prepared by resuspension in ethanol or complexation with MBCD (see above). Mevalonate was prepared by adding 385 µl 2.04 M KOH to 100 mg mevalonolactone (Sigma). The solution was heated (1 hr, 37°C) and adjusted to a 50 mM stock solution.

SDS-PAGE and immunoblotting {#s4-16}
---------------------------

Cells were collected mechanically in cold PBS or by trypsinisation, centrifuged (1000xg, 4 min, 4°C), and cell pellets resuspended in lysis buffer (1% (w/v) digitonin, 1x cOmplete protease inhibitor, 0.5 mM PMSF, 10 mM IAA, 2 mM NEM, 10 mM TRIS, 150 mM NaCl, pH 7.4). After 40 min incubation on ice, lysates were centrifuged (17.000xg, 15 min, 4°C), the post-nuclear fraction isolated and protein concentration determined by Bradford assay. Samples were adjusted with lysis buffer and 6 x Laemmli buffer +100 mM dithiothreitol (DTT) and heated at 50°C (15 min). Samples were separated by SDS-PAGE and transferred to PVDF membranes (Merck) for immunodetection. Membranes were blocked in 5% milk +PBST (PBS + 0.2% (v/v) Tween-20) (1 hr) and incubated with primary antibody in PBST +2% (w/v) BSA at 4°C overnight. For detection from whole-cell lysate, membranes were incubated in peroxidase (HRP)-conjugated secondary antibodies. For detection of immunoprecipitated proteins, TrueBlot HRP-conjugated secondary antibodies (Rockland) were used. Immunoprecipitated RNF145 was detected using Protein A-conjugated HRP.

Immunoprecipitation {#s4-17}
-------------------

Cells were seeded to 15 cm tissue culture plates (4\*10^6^ cells per plate). The following day, cells were washed five times with PBS and cultured in starvation medium (DMEM +10% LPDS+10 µM mevastatin +50 µM mevalonate +penicillin/streptomycin) for 20 hr. To prevent HMGCR membrane extraction and degradation, starved cells were treated with NMS-873 (50 µM) 0.5 hr prior to sterol addition (2 µg/ml 25-hydroxycholesterol and 20 µg/ml cholesterol for 1 hr) and collection in cold PBS. Cells were lysed in IP buffer 1 (1% (w/v) digitonin, 10 µM ZnCl~2~, 1x cOmplete protease inhibitor, 0.5 mM PMSF, 10 mM IAA, 2 mM NEM, 10 mM TRIS, 150 mM NaCl, ph 7.4), post-nuclear fractions isolated by centrifugation (17.000xg, 4°C, 15 min) adjusted to 0.5% (w/v) digitonin and pre-cleared with IgG Sepharose^TM^ 6 Fast Flow (1 hr). Endogenous RNF145 and V5-tagged RNF145 were immunoprecipitated at 4°C overnight from 3 to 6 mg whole-cell lysate using Protein A-Sepharose and anti-RNF145 or V5 antibody, respectively. Beads were collected by centrifugation (1500xg, 4 min, 4°C), washed for 5 min with IP buffer 2 (0.5% (w/v) digitonin, 10 µM ZnCl~2~, 10 mM Tris, 150 mM NaCl, pH 7.4) and 4 × 5 min with IP buffer 3 (0.1% (w/v) digitonin, 10 µM ZnCl~2~, 10 mM TRIS, 150 mM NaCl, pH 7.4). Proteins whose interaction with RNF145 was labile in the presence of 1% (v/v) Triton X-100 were recovered by eluting twice for 30 min with 20 µl TX100 elution buffer (1% (v/v) Triton X-100 +2 x cOmplete protease inhibitor in 10 mM TRIS, 150 mM NaCl pH 7.4) at 37°C under constant agitation. Immunoprecipitated RNF145 was subsequently eluted in 30 µl 2x Laemmli buffer +3% (w/v) DTT at 50°C (15 min). RNF145-V5 and associated complexes were recovered by two sequential elutions with V5 elution buffer (1 mg/ml V5 peptide +2 x cOmplete protease inhibitor in 10 mM TRIS, 150 mM NaCl pH 7.4) for 30 min at 37°C under continuous agitation. Eluted samples were adjusted with Laemmli buffer and denatured at 50°C (15 min).

Ubiquitination assays {#s4-18}
---------------------

Cells were sterol-depleted (20 hr), treated with 20 µM MG132 and left for 30 min before addition of sterols (2 µg/ml 25-hydroxycholesterol and 20 µg/ml cholesterol for 1 hr) or EtOH (vehicle control). Immunoprecipitation of ubiquitinated HMGCR was performed as described above from 1 mg whole-cell lysate and using rabbit α-HMGCR (Abcam, ab174830). Proteins were eluted in 30 µl 2x Laemmli buffer +100 mM DTT at 50°C (15 min). For immunoblotting of ubiquitin with mouse VU-1 α-ubiquitin (Life Sensors, VU101), the PVDF membrane was incubated with 0.5% (v/v) glutaraldehyde/PBS pH 7.0 (20 min) and washed 3x with PBS prior to blocking in 5% (w/v) milk +PBS + 0.1% (v/v) Tween-20.

Indirect immunofluorescence confocal microscopy {#s4-19}
-----------------------------------------------

Cells were grown on coverslips, fixed in 4% PFA (15 min), permeabilised in 0.2% (v/v) Triton X-100 (5 min) and blocked with 3% (w/v) BSA/PBS (30 min). Cells were stained with primary antibody diluted in 3% (w/v) BSA/PBS (1 hr), washed with 0.1% (w/v) BSA/PBS, followed by staining with secondary antibody in 3% BSA/PBS (1 hr), an additional washing step (0.1% (w/v) BSA/PBS) and embedded using ProLong Gold Antifade Mountant with DAPI (Thermo Fisher). Images were acquired using an LSM880 confocal microscope (Zeiss) at 64x magnification.

Statistical analysis {#s4-20}
--------------------

Statistical significance was calculated using the unpaired Student's t-test.

Data deposition {#s4-21}
---------------

Sequencing data from CRISPR/Cas9 knockout screens presented in this study have been deposited at the Sequence Read Archive (SRA) (genome-wide screen: SRP151225; ubiquitome screen: SRP151107).
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In the interests of transparency, eLife includes the editorial decision letter, peer reviews, and accompanying author responses.

\[**Editorial note:** This article has been through an editorial process in which the authors decide how to respond to the issues raised during peer review. The Reviewing Editor\'s assessment is that all the issues have been addressed.\]

Thank you for submitting your article \"The sterol-responsive RNF145 E3 ubiquitin ligase mediates degradation of HMG-CoA reductase together with gp78 and Hrd1\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Wade Harper as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Ivan Dikic as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Randy Y Hampton (Reviewer \#2). A further reviewer remains anonymous.

The Reviewing Editor has highlighted the concerns that require revision and/or responses, and we have included the separate reviews below for your consideration. If you have any questions, please do not hesitate to contact us.

Summary:

This paper employs a clever assay to perform a genome-wide CRISPR screen for genes that control sterol-dependent turnover of HMGCR in the ER membrane. This is an exciting paper that uncovers a clear role for RNF145 in turnover of HMGCR, with additional roles for gp78 and Hrd1. The identity to E3s regulating HMGCR turnover in mammals has been controversial, with some evidence for gp78 and TRC8 in its turnover, and some evidence against these proteins being involved. Given the important of the pathway in controlling lipid regulatory mechanisms, understanding the key regulatory mechanisms is important. A second interesting aspect of the paper is the autoregulation of RNF145 itself, probably through an auto-ubiquitylation mechanism, although the data need further clarification as described below. Overall, the biochemical and screening data is of very high quality and convincing.

The reviewers were all quite positive about the paper.

Major concerns:

Most of the comments raised had to do with aspects of the text. Several suggestions were made on ways to improve clarity and to explain particular aspects of what can be concluded from the results or what prior work might say. In particular, the sterol regulation of RNF145 is a bit counterintuitive, as indicated by both reviewers 2 and 3. So we would strongly suggest that this be addressed, at a minimum through changes in the text, and if possible through an experiment (see reviewer 3 comments). The reviewers also suggest that you discuss the previous paper on RNF145 in greater detail. We also feel that addressing point 5 by reviewer 3 would improve the paper, in the event that this data is available or could be obtained quickly.

Separate reviews (please respond to each point):

*Reviewer \#1:*

This paper reports a crispr screen leading to the identification of genes that control sterol-dependent turnover of HMGCR. The authors set up a cell line that reports on the abundance of a fluorescently tagged HMGCR protein (Figure 1) and performed a crispr screen (Figure 2). The identity to E3s regulating HMGCR turnover in mammals has been controversial, with some evidence for gp78 and TRC8 in its turnover, and some evidence against these proteins being involved. Given the important of the pathway in controlling lipid regulatory mechanisms, understanding the key regulatory mechanisms is important.

Through the genome wide screen, the authors identified Ube2g2 and RNF145 as regulators of HMGCR turnover. The show that gp78 and RNF145 are functionally redundant, and are backed up to a small degree by the Hrd1 E3. RNF145 itself has a relatively subtle phenotype and a secondary ubiquitylome screen in RNF145 null cells led to the identification of gp78 as the partially redundant function.

The authors have also found that RNF145 may be auto-regulated and is rapidly turned over under steady state conditions in a manner that requires its RING domain. They also found that its transcription and abundance is regulated by sterols and that the interaction of RNF145 with insig is sterol dependent, which are interesting findings and provide novel mechanistic insight.

Overall the paper is clear and to a large degree straightforward. The screening design is good. The results clarify the role for various E3s in HMGCR turnover, identify a new component, and deduce several regulatory aspects of the pathway. Overall, the paper is appropriate for *ELife*.

Minor:

1\) The deltaR/deltaG nomenclature is a bit confusing and it might be better to simply write RNF145-/-;gp78-/-.

Additional data files and statistical comments:

All the CRISPR screening data (Sequence reads) should be provided.

*Reviewer \#2:*

The paper by Menzies et al. out of the Lehrner lab is a typical example of the interesting and beautiful work that is routinely produced by this group. The experimental approach is clear and elegant (and I have never even heard of that fluorescent protein!). The data are clean and very informative, and the results are surprising and take us...some...or maybe most...of the way to resolving the Great Mammalian HMGcR Mystery.

If I understand the instructions to the reviewers, it is the case is that we are simply to provide suggestions; that this is an example of a new experimental mode of reviewing that makes it entirely up to the authors to accept suggestions and to respond or not as they see fit. That is a great development in terms of lessening the stranglehold that reviewers have on the fates of authors, and I approve, since I, and probably everyone who is reading this be them author or reviewer, has had that situation, where 50-60 thousand dollars later, the \"requested additional experiment\" didn\'t work or did work but didn\'t really enhance the strength of the paper. So good for *eLife*!

On the other hand, shoot, we already aren\'t getting paid, now we don\'t really have any authoritative say either. I feel more like a spectator in the courtroom, or a viewer of a newsfeed than a bone fide reviewer. But not a problem! This work is sufficiently well crafted that my optional suggestions will be offered in the spirit of optimistic encouragement.

1\) The TRC8 problem: so the one issue missing is the absence of any TRC8 dependence in these effects. I am comfortable with that; I think a lot of these differing results are due to subtilties of gene expression that change which ligases, or regulating factors, appear or do not in a given experiment. Any discussion-based explanations for this?

2\) A physiological model for RNF145\'s regulation: It is odd, is it not, that depleted sterols induce the E3 that will get rid of HMGCR induced by depleted sterols. What do you think the function may be? It would be interesting to hear what you think.

3\) RNF145 information: It might be useful to emphasize (I didn\'t see it in the paper but perhaps I missed it) that RNF145 has a large transmembrane domain with an SSD. The SSD is an incredibly interesting module in biology, and especially sterol biology, and it should at least be mentioned.

4\) The misfolding/quality control connection to HMGCR regulation: One of the very lovely things about this work is that the authors, through estimable and intense hard work, unveiled a role for the eponymous E3 of HMGCR regulation, namely Hrd1, when enough ligases are taken out of the picture. This is very cool. Two things. First, it is worth mentioning the earlier Debose-Boyd work showing that when mammalian HMGCR is expressed in *Drosophila* cells with the corresponding mammalian INSIG, one can observed, amazingly enough, *Drosophila* Hrd1 dependent. sterol-regulated degradation of the exogenous HMGCR. In fact this is a feature of a \"misfolding-based\" explanation for the HMGCR ligase dilemma that is also nicely supported by the work of these new studies. The idea being that in the original HRD system, that is yeast Hmg2 regulation by Hrd1 (nicely referenced in this new work), regulated misfolding is at the heart of that version of HMGCR regulation. Since protein quality control often can be mediated by a number of ligases that share ability to recognize misfolding, in the case of the mammal, perhaps regulated misfolding also plays a role: maybe the ability of different groups to observed different ligase dependencies is due to a certain shared ability among distinct ligases to recognize a regulated misfolding event as part of ligand-mediated control of HMGCR stability. Thus, the higher flexibility of quality control based regulation might allow a number of distinct quality control ligases to participate depending on details of presence, levels, and cell type. It is only one explanation, but it is an interesting one, and one we described in some detail and would appreciate you referencing from our Annual Reviews of Cell and Developmental Biology (Wangeline, Vashistha and Hampton, 2017). In fact we even suggest that this would be one place where CRISPR based analysis would provide some tests and resolution of this idea. Of course, I am biased a little, since I am Hampton, one of the authors. But it would be resonant with your new work and my recently graduated, first author student would also really appreciate it too.

Anyway, beautiful work. Congratulations!

Additional data files and statistical comments:

Very rigorous.

*Reviewer \#3:*

Starting from a clever CRISPR screen, the authors report that the ER E3 ligase RNF145 cooperates with gp78 to control the sterol-regulated degradation of HMGCR. In their absence, Hrd1 acts in this role. Together, these 3 ER E3 ligases account for HMGCR sterol-regulated degradation in HeLa cells. The data are clearly presented and support the conclusions. The findings are consistent with a JBC paper published in March 2018 showing a role for RNF145 in HMGCR degradation in CHO cells. These findings are clinically important since they pertain to control of HMGCR protein levels and statin therapy and will be of interest to a broad audience.

Major comments:

1\) Authors conclude that the HMGCR-Clover gene is present at a single locus and that these cells express endogenous HMGCR from another allele. This is based on the presence of HMGCR that co-migrates with HMGCR in parent cells. However, this could be due to proteolytic cleavage between HMGCR and Clover. This conclusion should be validated by PCR-sequencing.

2\) The authors should include in their discussion comments on whether other genes identified in screens are likely to be positive hits and why. For example, is GALNT11 a true positive? Why might they have gotten EHD1? Could this disrupt LDLR trafficking, which was also found?

3\) Zelcer and colleagues reported that RNF145 is an LXR target gene and induced by LXR agonist (Cook et al., 2017). LXR is typically activated under conditions of cholesterol excess. However, the authors find the opposite. Rather RNF145 is induced under sterol depleted conditions. To address this discrepancy, suggest that authors test effects of LXR agonist in parallel to sterol depletion in their cells and discuss these results.

4\) These studies were obviously performed in parallel to those described in Jiang et al., 2018. While the authors mention this paper, they should discuss their own results in the context of this other study.

5\) Evidence for a RNF145-Insig-HMGCR complex is strong. However, the authors depict RNF145 binding to Insig directly and not HMGCR in Figure 8. Suggest that authors test whether the RNF145-HNGCR interaction requires Insig1/2 to support this model or cite the work of others as support for this specific depiction.

Minor comments:

1\) Please describe in the results why the p97 inhibitor was included in Figure 6 experiments and whether addition is required for interaction.

2\) Figure 8 is a beautiful figure. However, the arrows next to STEROLS in the center are somewhat confusing and appear to indicate that sterols are moving between the top and bottom panels. Suggest writing \"Low sterol\" and \"High sterol\" or something similar to improve figure clarity.

3\) To improve clarity, please describe in more detail the biology behind the US2-MHC1 assay used to validate TRC8 knockout.

4\) Introduction paragraph three is missing a word, \"despite confirming a for gp78\"

5\) Results first paragraph subheading, typo HMMGCR.

10.7554/eLife.40009.038

Author response

Reviewer \#1:

> \[...\] Overall the paper is clear and to a large degree straightforward. The screening design is good. The results clarify the role for various E3s in HMGCR turnover, identify a new component, and deduce several regulatory aspects of the pathway. Overall, the paper is appropriate for ELife.
>
> Minor:
>
> 1\) The deltaR/deltaG nomenclature is a bit confusing and it might be better to simply write RNF145-/-;gp78-/-.

Thank you for this suggestion. We did try this out, but due to simplicity and spatial constraints we think that the designation 'ΔRΔG' is equally appropriate as long as it is clearly stated in the figure legends and text. We prefer to avoid using the denomination '-/-', since it implies complete knockout in a diploid system, while in HeLa cells ploidy is altered.

> Additional data files and statistical comments:
>
> All the CRISPR screening data (Sequence reads) should be provided.

Raw sequence reads have been deposited on the Sequence Read Archive (SRA). Deposition IDs are listed in the Materials and methods section "Data deposition".

Reviewer \#2:

> The paper by Menzies et al. out of the Lehrner lab is a typical example of the interesting and beautiful work that is routinely produced by this group. \[...\] This work is sufficiently well crafted that my optional suggestions will be offered in the spirit of optimistic encouragement.
>
> 1\) The TRC8 problem: so the one issue missing is the absence of any TRC8 dependence in these effects. I am comfortable with that; I think a lot of these differing results are due to subtilties of gene expression that change which ligases, or regulating factors, appear or do not in a given experiment. Any discussion-based explanations for this?

We are aware of the TRC8 controversy and have worked with this ligase for many years. Throughout this project, despite extensive testing, we have never seen any involvement of TRC8 in the degradation of HMGCR in HeLa cells -- consistent with the findings of the Weissman group. Clearly, we cannot absolutely rule out that TRC8 might play a role in HMGCR degradation in other cell lines or under different conditions. However, we are confident that in all the cell lines that we have tested, where we see a striking role for TRC8 in the HCMV-US2-mediated degradation of MHC-I and a host of other immunoreceptors (Stagg et al., 2009; Hsu et al., 2015), we are unable to see any role for TRC8 in HMGCR degradation.

> 2\) A physiological model for RNF145\'s regulation: It is odd, is it not, that depleted sterols induce the E3 that will get rid of HMGCR induced by depleted sterols. What do you think the function may be? It would be interesting to hear what you think.

Our finding that sterol depletion induces RNF145 levels while HMGCR remains stable may at first seem somewhat counterintuitive. However, RNF145 is not associated with either the Insigs or HMGCR under these conditions (Figure 6A-C). We would therefore argue that the build-up of RNF145 under sterol depletion anticipates and facilitates rapid removal of HMGCR, once homeostasis is restored. This point has now been included in the Discussion section:

"While this sterol-dependent transcriptional increase in RNF145 expression may at first seem counterintuitive, under sterol-deplete conditions the RNF145 ligase is not engaged with Insigs or its HMGCR substrate. The build-up of RNF145 predicts the restoration of sterol concentrations allowing RNF145 to immediately engage with, and degrade its HMGCR substrate. Thus the build-up of RNF145 anticipates its critical role in the restoration of cellular cholesterol homeostasis."

> 3\) RNF145 information: It might be useful to emphasize (I didn\'t see it in the paper but perhaps I missed it) that RNF145 has a large transmembrane domain with an SSD. The SSD is an incredibly interesting module in biology, and especially sterol biology, and it should at least be mentioned.

We agree that this is an incredibly interesting module and did mention the presence of a putative SSD in RNF145 in both the results and the Discussion section of the original submission. We were, and still are, excited by this module and have made a number of mutations in the SSD of RNF145. Unfortunately this so destabilised the RNF145 protein that it was impossible to obtain any meaningful results. We have emphasised the potential contribution of the SSD to RNF145 activity:

*"*Like HMGCR and SCAP, RNF145 contains a putative sterol-sensing domain in its transmembrane region (Cook et al., 2017), suggesting that sterols may facilitate RNF145's association with Insigs. In contrast to Jiang et al., who reported a constitutive, sterol-independent association between ectopically expressed RNF145 and Insig-1 or -2, we find that endogenous RNF145 interacts with endogenous Insig-1 in a sterol-dependent manner (Figure 6C), as reported for the interaction of SCAP and HMGCR with the Insig proteins (Lee et al., 2007). The binding of RNF145 to Insig-1 is HMGCR-independent (Figure 6D). Furthermore, in the absence of Insigs, the RNF145-HMGCR association is lost (Figure 6E), implying that the interaction between these two proteins is absolutely Insig-dependent. Therefore, sterols trigger the recruitment of RNF145 to HMGCR via Insigs, leading to HMGCR ubiquitination and degradation. This ability of RNF145 to rapidly bind Insigs following sterol availability supports a key role for this ligase in HMGCR regulation."

> 4\) The misfolding/quality control connection to HMGCR regulation: One of the very lovely things about this work is that the authors, through estimable and intense hard work, unveiled a role for the eponymous E3 of HMGCR regulation, namely Hrd1, when enough ligases are taken out of the picture. This is very cool. Two things. First, it is worth mentioning the earlier Debose-Boyd work showing that when mammalian HMGCR is expressed in Drosophila cells with the corresponding mammalian INSIG, one can observed, amazingly enough, Drosophila Hrd1 dependent. sterol-regulated degradation of the exogenous HMGCR. In fact this is a feature of a \"misfolding-based\" explanation for the HMGCR ligase dilemma that is also nicely supported by the work of these new studies. The idea being that in the original HRD system, that is yeast Hmg2 regulation by Hrd1 (nicely referenced in this new work), regulated misfolding is at the heart of that version of HMGCR regulation. Since protein quality control often can be mediated by a number of ligases that share ability to recognize misfolding, in the case of the mammal, perhaps regulated misfolding also plays a role: maybe the ability of different groups to observed different ligase dependencies is due to a certain shared ability among distinct ligases to recognize a regulated misfolding event as part of ligand-mediated control of HMGCR stability. Thus, the higher flexibility of quality control based regulation might allow a number of distinct quality control ligases to participate depending on details of presence, levels, and cell type.

This is a very interesting hypothesis and, we agree, not necessarily mutually exclusive with Insig-mediated HMGCR degradation in mammals. We have adjusted our Discussion section to that effect and included additional references:

*"*Our finding that Hrd1 is only involved in HMGCR regulation when the other two ligases are absent, suggests that under sterol-rich conditions, and in the absence of RNF145 or gp78, conformational changes in the sterol-sensing domains of HMGCR may lead to a less ordered state and be recognised and targeted by the Hrd1 quality control pathway. Ligand-induced selective and reversible local misfolding in Hmg2p, dubbed "mallostery", is a suggested mode of recognition by Hrd1p (Wangeline et al., 2017; Wangeline and Hampton, 2018)."

*"*The mechanism underlying recognition of HMGCR by Hrd1 is unclear, and whether the Hrd1 complex directly recognises sterol-induced structural changes as seen with Hmg2 degradation in yeast is unknown. Hrd1 might utilise the Insig proteins as scaffolds for HMGCR binding. This is partially borne out in the complete rescue of HMGCR in Insig-1 and -2 depleted cells (Figure 1F). These mechanisms are not mutually exclusive and suggest that the contributions by different ligases may represent a regulated misfolding event as part of a ligand-mediated control of HMGCR stability. Further investigation is needed to clearly determine their contribution to HMGCR regulation."

> It is only one explanation, but it is an interesting one, and one we described in some detail and would appreciate you referencing from our Annual Reviews of Cell and Developmental Biology (Wangeline, Vashistha and Hampton, 2017). In fact we even suggest that this would be one place where CRISPR based analysis would provide some tests and resolution of this idea. Of course, I am biased a little, since I am Hampton, one of the authors. But it would be resonant with your new work and my recently graduated, first author student would also really appreciate it too.
>
> Anyway, beautiful work. Congratulations!

Reviewer \#3:

> \[...\] These findings are clinically important since they pertain to control of HMGCR protein levels and statin therapy and will be of interest to a broad audience.
>
> Major comments:
>
> 1\) Authors conclude that the HMGCR-Clover gene is present at a single locus and that these cells express endogenous HMGCR from another allele. This is based on the presence of HMGCR that co-migrates with HMGCR in parent cells. However, this could be due to proteolytic cleavage between HMGCR and Clover. This conclusion should be validated by PCR-sequencing.

The reviewer is correct. To further validate the HMGCR-Clover cell line we PCR-amplified and sequenced the HMGCR knock-in locus, including flanking sequences, to distinguish between the wild type and endogenously tagged HMGCR. Results are now shown in a new supplemental figure (Figure 1---figure supplement 1). This confirms the presence of both modified and unmodified HMGCR. These data have been referenced in the Results section:

"Residual, untagged HMGCR detected by immunoblot analysis in the reporter cells under sterol-depleted conditions suggested that at least one HMGCR allele remained untagged (Figure 1C, compare lanes 2 and 5), which was confirmed by PCR-amplification and sequencing of the genomic locus (Figure 1---figure supplement 1A-C)."

A new figure legend for Figure 1---figure supplement 1 was added:

"Figure 1---figure supplement 1. Genotyping of HMGCR-Clover knock-in cells.

\(A\) Schematic representation of PCR amplification of the genomic locus targeted for Clover insertion in HMGCR-Clover knock-in (KI) cells. Primers ('1', '2') specifically annealing in the 5' and 3' homology arms flanking the Clover gene sequence were used to amplify a region encompassing 347 bp (i) in the WT allele and 1122 bp (ii) if the Clover insert is present.

\(B\) The PCR reaction described in (A) was performed using genomic DNA derived from parental (WT) and HMGCR-Clover knock-in HeLa cells. Amplicons derived from the unmodified (WT, 347 bp) and HMGCR-Clover knock-in allele (KI, 1122 bp) are indicated. As described in Figure 1C, HeLa HMGCR-Clover KI cells retain at least one unmodified HMGCR allele in addition to endogenously Clover-tagged HMGCR.

\(C\) Genetic profiling of the HMGCR-Clover KI locus in HMGCR-Clover HeLa cells. The longer 1122 bp PCR product, obtained as described in (A), was isolated by agarose gel electrophoresis and confirmed by Sanger sequencing."

> 2\) The authors should include in their discussion comments on whether other genes identified in screens are likely to be positive hits and why. For example, is GALNT11 a true positive? Why might they have gotten EHD1? Could this disrupt LDLR trafficking, which was also found?

Thank you for raising this point. Genes identified in the genome-wide screen did include a number of unexpected hits. Several of these candidates were subsequently validated, therefore representing true-positives. A discussion of their involvement in HMGCR degradation has now been included in the revised manuscript:

"For a small number of validated hits from our screen (Figure 2C, Figure 2---figure supplement 1D), the effects on sterol-accelerated HMGCR degradation were unanticipated and likely reflect wide-ranging alterations to the protein and lipid environment. Trans-2,3-enoyl CoA reductase (TECR) catalyses the final steps in the synthesis of very long-chain fatty acids (VLCFAs) (Moon and Horton, 2003) as well as the saturation step in sphingolipid degradation (Wakashima et al., 2014). Polypeptide N-acetylgalctosaminyltransferase 11 (GALNT11) initiates protein O-linked glycosylation, suggesting that a protein involved in HMGCR regulation requires O-linked glycosylation (Schwientek et al., 2002). Interestingly, our screen revealed that loss of the LDLR impaired HMGCR-Clover degradation. This finding is unexpected as the cholesterol added to the cells to induce HMGCR degradation was not in the form of LDL. EH domain-containing protein 1 (EHD1) is required for the internalisation and recycling of several plasma membrane receptors, including the LDLR (Naslavsky et al., 2007; Naslavsky and Caplan, 2011) and loss of EDH1 impairs LDLR trafficking with decreased intracellular cholesterol levels (Naslavsky et al., 2007). The other significant hits in the screen (PPAP2C, FER) have not been validated."

> 3\) Zelcer and colleagues reported that RNF145 is an LXR target gene and induced by LXR agonist (Cook et al., 2017). LXR is typically activated under conditions of cholesterol excess. However, the authors find the opposite. Rather RNF145 is induced under sterol depleted conditions. To address this discrepancy, suggest that authors test effects of LXR agonist in parallel to sterol depletion in their cells and discuss these results.

We thank the reviewer and we are aware of this discrepancy. Data presented in our study (Figure 5C, D) show a clear transcriptional induction of RNF145 under conditions of sterol depletion, correlating with a comparable fold-increase of RNF145 protein levels. We agree that this finding suggests a different mechanism of RNF145 transcriptional control from the Zelcer lab study (Cook et al., 2017), where treatment with an LXR agonist induced a small increase in RNF145 transcription. Despite the claims in the title of this paper this increase (Figure 1B Cook et al., 2017) was only 1.2 -- 1.8 fold. Since LXRs are usually active under conditions of cholesterol excess, this is at odds with our observations. To clarify this discrepancy, we tested the effect of LXR induction on endogenous RNF145 mRNA and protein levels under sterol-depleted or --replete conditions in our system. Our new findings are now shown in Figure 5---figure supplement 2 and summarised below.

Treatment of HeLa cells with the LXR inducer GW3965 (also used in Cook et al., 2017), did not affect RNF145 mRNA levels, in clear contrast to the *bona fide* LXR target gene ABCA1, whose gene product was markedly increased (Figure 5 ---figure supplement 2A, compare lanes 2 and 4 with lanes 1 and 3). Similarly, we did not observe a significant potentiating effect of LXR induction on RNF145 transcript levels under sterol-depleted conditions (Figure 5---figure supplement 2B). Our results clearly demonstrate that sterol depletion -- not excess -- favours RNF145 transcription.

These new findings have been incorporated into the Discussion section:

"RNF145 transcription was reported to be regulated by the sterol-responsive Liver X Receptor (LXR) family of transcription factors (Cook et al., 2017; Zhang et al., 2017), which transcriptionally activate cholesterol efflux pumps (ABCA1, ABCG1) (Costet, 2000; Edwards et al., 2002) and the IDOL E3 ubiquitin ligase, which targets the LDLR for degradation (Zelcer et al., 2009). Pharmacological treatment of HeLa cells with the LXR inducer (GW3965) increased protein levels of ABCA1, but RNF145 transcript levels were not significantly increased (Figure 5---figure supplement 2A/B). In HeLa cells, therefore, the increased expression of RNF145 following cholesterol starvation is not primarily driven by the LXR pathway."

A new figure legend for Figure 5---figure supplement 2 has been added:

"Figure 5---figure supplement 2. Increased RNF145 transcription upon sterol depletion is LXR-independent.

\(A\) Hela cells were sterol-depleted (SD, 10% LPDS + 10 μM mevastatin + 50 μM mevalonate) for 48 h in the presence of the synthetic LXR ligand GW3965 (1 μM) or DMSO (vehicle control). Whole--cell lysates were analysed by SDS-PAGE and immunoblot assay. Representative of ≥ 3 independent experiments.

\(B\) HeLa Cells were treated as described in (A) and the expression of indicated genes determined by quantitative PCR. All values were normalised to the steady-state, DMSO treated condition (bars 1 and 5). Mean ± S.D. (n = 3) and significance are indicated, unpaired Students t-test: \*\*p ≤ 0.01, \*\*\*p ≤ 0.001, n.s. not significant."

> 4\) These studies were obviously performed in parallel to those described in Jiang et al. JBC 2018. While the authors mention this paper, they should discuss their own results in the context of this other study.

Where appropriate, we have now placed our findings in context of the parallel study (Jiang et al., 2018):

"During preparation of this manuscript, the combined involvement of RNF145 and gp78 in Insig-mediated HMGCR degradation in hamster (CHO) cells was also reported (Jiang et al., 2018), confirming the role for these ligases in other species."

"In contrast to Jiang et al., who reported a constitutive, sterol-independent association between ectopically expressed RNF145 and Insig-1 or -2, we find that endogenous RNF145 interacts with endogenous Insig-1 in a sterol-dependent manner (Figure 6C), as reported for the interaction of SCAP and HMGCR with the Insig proteins (Lee et al., 2007). The binding of RNF145 to Insig-1 is HMGCR-independent (Figure 6D). Furthermore, in the absence of Insigs, the RNF145-HMGCR association is lost (Figure 6E), implying that the interaction between these two proteins is absolutely Insig-dependent. Therefore, sterols trigger the recruitment of RNF145 to HMGCR via Insigs, leading to HMGCR ubiquitination and degradation. This ability of RNF145 to rapidly bind Insigs following sterol availability supports a key role for this ligase in HMGCR regulation."

> 5\) Evidence for a RNF145-Insig-HMGCR complex is strong. However, the authors depict RNF145 binding to Insig directly and not HMGCR in Figure 8. Suggest that authors test whether the RNF145-HNGCR interaction requires Insig1/2 to support this model or cite the work of others as support for this specific depiction.

We agree that our model, as depicted in Figure 8, shows RNF145 binding to HMGCR via the intermediary Insig proteins, and we did not exclude a direct interaction between RNF145 and HMGCR. Our initial attempts to assess this issue with endogenous proteins were technically unsuccessful. However, spurred on by the reviewers' comments, this experiment has now been successful and we now include additional data which supports our model (Figure 6D, E, and Figure 6---figure supplement 1 for validation of the Insig1+2 knockout cell line). Using the immunoprecipitation strategy employed in Figure 6C, we show that (i) RNF145 still binds Insig-1 in the absence of HMGCR (Figure 6D), and importantly, (ii) RNF145 binding to HMGCR is lost upon Insig deletion (Figure 6E).

Figure 6---figure supplement 1 describes how Insig-1+2 knockout cells have been derived and validated. In short, combined CRISPR/Cas9-mediated knockout of both Insigs resulted in constitutive, sterol-independent upregulation of the HMGCR-Clover reporter (see Figure 1F). This strong phenotype was used to enrich for an Insig-1 and -2 depleted population (Figure 6---figure supplement 1A, B(i)) and isolation of ΔInsig-1+2 single cell clones (Figure 6---figure supplement 1B(ii), C).

We reference these findings in the Results section:

"Binding of RNF145 to Insig-1 was HMGCR-independent (Figure 6D), and in the absence of Insigs, RNF145 was unable to bind HMGCR (Figure 6E, see Figure 6---figure supplement 1A-C for generation of Insig-1+2 knockout cells). Insigs are therefore indispensable for the interaction between RNF145 and HMGCR. These findings emphasize the central role of Insig proteins as scaffolds in the sterol-induced engagement of HMGCR by RNF145."

The legend accompanying Figure 6 has been expanded appropriately:

"(D -- E) Insigs mediate binding between RNF145 and HMGCR.

\(D\) HeLa UBE2G2 knockout cells (ΔUBE2G2 \#1) transfected with a pool of 4 sgRNAs targeting HMGCR (gHMGCR) or sgRNA targeting B2M (gCTR), transfected cells enriched by puromycin selection, and sterol-depleted for 20 h, before adding back sterols for 1 h + NMS-873 (10 μM, 1.5 h). Endogenous RNF145 was immunoprecipitated and Insig-1 and HMGCR detected by immunoblot analysis. Non-specific bands are designated by an asterisk (\*).

\(E\) HMGCR-Clover HeLa WT or Insig-1+2 knockout (ΔIn-1+2) cells were transfected with a pool of three gRNAs targeting UBE2G2 (gUBE2G2) and treated as in (D). Non-specific bands are designated by an asterisk (\*)."

The generation and validation of the Insig-1+2 double knockout cells is shown in a new supplemental figure (Figure 6---figure supplement 1) with the accompanying figure legend:

"Figure 6---figure supplement 1. Generation of Insig knockout cell lines.

\(A\) HeLa HMGCR-Clover cells expressing Cas9 were transfected with 4 sgRNAs targeting Insig-1 and Insig-2 (ΔInsig-1+2), and selected with puromycin. Due to the low initial enrichment of Insig-1+2 double knockouts in this experiment, double knockouts were further enriched by two consecutive rounds of FACS ('sort \#1' and 'sort \#2'), selecting cells with high constitutive HMGCR-Clover expression ('sorted', red box) after overnight sterol depletion (SD) and sterol repletion (S) for 2 h. r.u., relative units.

\(B\) Immunoblotting for endogenous Insig-1 in cells isolated from sort \#1 and \#2 in (A) (i) and in the Insig-1+2 double knockout clone (ΔIn-1+2 clone) isolated from the enriched population in sort \#2 (ii). Insig-2 expression could not be assessed by immunoblotting due to the lack of a working Insig-2 antibody and/or low expression levels in these cells.

\(C\) Validation of the Insig-1+2 double knockout clone isolated by single-cell sorting from the sort \#2 population in (A). Loss of both Insigs was confirmed by presence of sterol-independent, constitutive expression of HMGCR-Clover due to de-repression of the SCAP-SREBP2 complex (red line). HMGCR-Clover expression under steady-state conditions in Insig-1+2 double knockout cells is comparable to that of the sterol-depleted (SD, 20 h) parental WT cell line (blue line). Loss of Insig-1 in the Insig-1/2 double knockout single cell clone was further confirmed by immunoblotting (see (B) and Figure 6E)."

> Minor comments:
>
> 1\) Please describe in the results why the p97 inhibitor was included in Figure 6 experiments and whether addition is required for interaction.

We show that RNF145 interacts with HMGCR and Insig proteins in a sterol-dependent manner. Once RNF145 binds HMGCR, it would mediate the ubiquitination and subsequent degradation of its substrate. The VCP inhibitor is therefore necessary to efficiently capture this transient interaction and prevent otherwise rapid HMGCR degradation. A similar strategy has been described to facilitate the efficient enrichment and identification of ERAD substrates (Huang et al., 2018). Of note, the VCP inhibitor can be omitted in UBE2G2 knockout cells since the ubiquitination reaction is blocked by the lack of the E2 enzyme.

> 2\) Figure 8 is a beautiful figure. However, the arrows next to STEROLS in the center are somewhat confusing and appear to indicate that sterols are moving between the top and bottom panels. Suggest writing \"Low sterol\" and \"High sterol\" or something similar to improve figure clarity.

Thank you for this suggestion; we have now clarified the labelling in Figure 8.

> 3\) To improve clarity, please describe in more detail the biology behind the US2-MHC1 assay used to validate TRC8 knockout.

We are grateful for pointing out this omission and have now included a more detailed description of the results in the legend to Figure 7B---figure supplement 2:

"(B) TRC8 knockdown was confirmed by US2-mediated TRC8-dependent downregulation of MHC-I. HeLa cells transiently expressing either B2M sgRNA (gCTR) or TRC8-sepcific sgRNAs (gTRC8) were selected for puromycin resistance and transduced with a lentiviral US2 and/or TRC8 construct 5 days *post* transfection. Cell-surface MHC-I staining and FACS analysis were performed on day 10 *post* transfection. US2 is a herpes cytomegalovirus (HCMV)-encoded gene product which directs TRC8 to degrade MHC-I in the ER lumen (Stagg et al., 2009; Hsu et al., 2015). Loss of TRC8 renders cells resistant to US2-mediated MHC-I loss (green line in histogram) and therefore serves as a functional readout for TRC8 status."

> 4\) Introduction paragraph three is missing a word, \"despite confirming a for gp78\"

Thank you, the amended sentence now reads:

"However, these findings remain controversial as, despite confirming a role for gp78 in the regulation of Insig-1 (Lee et al., 2006; Tsai et al., 2012), an independent study found no evidence for either gp78 or TRC8 in the sterol-induced degradation of HMGCR (Tsai et al., 2012). Therefore, the E3 ligase(s) responsible for the sterol-accelerated degradation of HMGCR remain disputed."

> 5\) Results first paragraph subheading, typo HMMGCR.

Thank you, we have corrected this typographical error to "HMGCR".

[^1]: Department of Medicine, Brigham and Women\'s Hospital, Boston, United States.

[^2]: These authors contributed equally to this work.
